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INTRODUCTION 
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Cervical cancer remains an important problem, most importantly in developing countries 
where it is associated with high incidence and increased mortality. It has a potential for 
prevention with effective screening program. Cervical cancer is the fourth most common 
cancer in women, and the seventh overall, with an estimated 528,000 new cases in 
2012(1).Based on report by Indian council of Medical Research, 20-35 per 1,00,000 
women were affected by  cervical cancer in India between age group of 33 to 65 years, 
whereas in developed countries it varies from 1 to 8 cases per 1,00,000 women. 
 
Pap smear is considered as one of the best screening tests in medicine and it has reduced 
the incidence of cervical cancer significantly to more than 50% (2). However, the 
limitation of Pap test is its wide range of sensitivity to detect cervical precancerous 
lesions.  Infection with high-risk human papillomaviruses (hr-HPV) for longer period of 
time has been identified as the important causal factor for developing high-grade cervical 
intraepithelial neoplasia (CIN) and increase the chance for progression to cervical 
carcinoma.   
 
Testing for the hr- HPV types is referred to as HPV DNA testing. This test is being 
increasingly used in screening cervical cancer and can be performed from cytology 
samples.  These tests are suggested for women more than 30 years and diagnosed with 
ASC-US and LSIL by Pap smear.  But HPV DNA testing is not suggested in women less 
than 30 years due to the more number of HPV infections in this age group. These 
infections are of high transient nature. Therefore, to improve the screening process, 
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current standard protocol being followed in the Gynecology outpatient department of 
CMC is to test for HPV DNA if cervical cytology is suggestive of ASC-US or LSIL. This 
further directs the clinician to recommend colposcopy.  
 
hr-HPV DNA tests increase the identification of number of women with high grade 
lesions. This testing has improved sensitivity compare to cervical cytology but has lower 
specificity. A Few host cell biomarkers were assessed to improve the specificity of 
cervical screening(3). P16INK4A is one such host cell biomarker which has been 
recently identified. This is also called as P16 which is a cyclin dependent kinase inhibitor. 
This is used as a cellular protein marker(4).  
 
Combining p16 with ki-67 proliferation marker, detects transformed HPV cells which are 
undergoing uncontrolled proliferation. Many studies have assessed the clinical utility 
p16/ki-67dual immunocytochemistry for detecting of high grade (≥ CIN 2) lesions(5). 
The purpose of this study is to assess the significance of p16/ki67 immunocytochemistry 
in improving the efficiency of the screening system for cervical cancer. 
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AIM:  
 
• To assess the significance of P16INK4a/ki67 immunocytochemistry in improving 
the predictive value for high grade cervical intraepithelial (≥ CIN2) lesions on Pap 
smears. 
 
Objectives: 
• To identify 100 consecutive cases of ASC-US/LSIL/ASC-H/HSIL on thin prep 
pap smears in women aged more than 25 years. 
 
• To perform, interpret and correlate the results of p16/Ki67immunocytochemistry 
on these thin prep cervical smears with histopathological features and high-risk 
HPV DNA. 
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The earliest description regarding cervical intraepithelial pre-cancerous lesion was given 
by Sir John Williams in 1888(6). Originally the term carcinoma in situ was coined by 
Broders to describe lesions on cervical biopsies that was composed of cells that 
morphologically similar to carcinoma, but without invasion of the basement 
membrane(7). 
However, by the early 1950s, it became evident that there were surface lesions that had 
abnormal histopathological features which did not fulfil the carcinoma in situ criteria. 
These lesions had less risk for subsequent development for cancer. In 1952, Reagen and 
Hicks coined the term 'atypical hyperplasia' to describe these histopathological lesions. 
However in the subsequent year, they replaced this term with dysplasia, which was 
further graded as mild, moderate and severe(8). Albeit, the most profound change in 
cervical histopathological terminology came about in 1969, when Richart proposed that 
carcinogenesis in the cervix was a continuum of disease that begins as mild dysplasia and 
progresses through mild, moderate, and severe dysplasia to carcinoma in situ. He 
therefore proposed that the artificial terminological distinction between dysplasia and 
carcinoma in situ be abandoned and coined the term 'cervical intraepithelial neoplasia' to 
emphasize its association with cancer(9). 
The CIN terminology became the most widely accepted histopathological terminology 
for cervical cancer precursors in the late 1970s. The CIN terminology divided 
precancerous cervical lesion into 3 groups: CIN 1 corresponds to mild dysplasia, CIN 2 
corresponds to moderate dysplasia, and CIN 3 to both severe dysplasia and carcinoma in 
situ. At the onset of this classification, CIN was thought to define a spectrum of cervical 
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precancerous lesions, which shared common etiology and histological changes. Infection 
with high-risk types of HPV plays an important etiology for the development of cervical 
cancer. Thus, a new model of cervical carcinogenesis has been developed. This model 
has three discrete steps: Initial infection with a high-risk type of HPV, progression to a 
histologically defined precursor lesion that requires persistence of the HPV infection, and  
invasion(10,11). 
Based on above model, the spectrum of histological changes that are referred to as CIN 
do not represent a single disease process at different stages in its development but instead 
two distinct biological entities, one a productive viral infection and the other a true 
neoplastic process confined to the epithelium(12). The screening test for cervical cancer 
in the last 70 odd years has been the Papanicolaou test which is also known as Pap smear 
or Pap test. It was developed by Georgios Papanicolaou in 1940. The cytopathology also 
had a similar terminology problem before the Bethesda conferences. The previous 
terminology in cytology was mild, moderate and severe dysplasia. These conferences 
proposed a new terminology for reporting cervical cytology. Now this is commonly 
known as The Bethesda System (TBS) which created standard reporting terms and 
criteria for each interpretive category(13). 
This terminology uses the term low-grade squamous intraepithelial lesion (LSIL) for 
lesions previously categorized  as  CIN 1/low grade dysplasia and high-grade squamous 
intraepithelial lesion (HSIL) for lesions previously known as CIN 2/moderate dysplasia 
and CIN 3/high grade dysplasia(14,15). 
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Squamous intraepithelial lesion (SIL) with only two gradations (low and high grade) 
reflects the different biologic states of productive HPV infections versus lesions with a 
higher risk of transitioning to precancer and ultimately cancer. The Bethesda System also 
enabled the development of clinical management guidelines linked to these standardized 
terminologies. The Bethesda System(TBS) for cervical cytology supported a two-tiered 
classification. 
Promotion of a 2-tiered terminology for histology in the 1990s was not supported by 
professional organizations, hence this terminology for histopathological report was never 
widely adopted. The 2001 and 2006 American society of colposcopy and cervical 
pathology (ASCCP) Consensus Guidelines and World Health Organization (WHO) used 
a 2-tiered terminology for cervical precancerous lesion, except in adolescents and young 
women with CIN 2 and CIN 3 (16,17). At present, WHO and 2012 ASCCP Consensus 
Guidelines for the clinical management of cervical histological abnormalities, uses a 2-
tiered terminology for precancerous cervical lesions(18) i.e. LSIL and HSIL.  
The primary aim in using a 2-tiered system for reporting cervical histology in young 
women and adolescents is that, there can be expectant management of CIN 2 with the 
option to follow up, but not for CIN 3 which needs early intervention (18).  The 2-tiered 
system better reflects the association between the biology of HPV with precancerous 
cervical lesions and also helps in  management(19). 
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 Discordance between cytology and histopathology: 
In USA, the median reporting rate of ASCUS is 4.7% according to a 2003 survey by 
College of American Pathology and median reporting rate of ASC-H  in 2003 was 
0.4%(20).  Data obtained from the College of American Pathologists (CAP) show that, in 
2006 the median rate for LSIL was 2.5 % and HSIL was 0.5%.  They also found that, 
there is an overall 10–15 % inter- pathologist discordance rate between the diagnosis of 
LSIL and HSIL interpretations in cervical cytology (21). It was found that, 15–25 % of 
women with LSIL in cytology are found to have CIN 2+ lesions in histopathology(22). 
 
Etiology: 
Major risk factors for cervical cancer are presence of high-risk types of HPV and lack of 
cervical screening. Factors such as smoking, use of oral contraceptive and 
immunosuppression may result in increase in the risk for cervical carcinoma in women 
infected with high-risk types of HPV(23).  
 
Pathogenesis: 
In the late 1970s, Dr. Harald Zur Hausen proposed that there might be an association 
between HPV and precancerous and cancerous cervical lesion(24). A large number of 
epidemiological studies subsequently linked infection by specific types of HPV to the 
development of anogenital cancers. Presence of high-risk HPVs play a critical role in the 
development of most precancerous and cancerous cervical lesions (25).  
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The human papilloma viruses belong to the genus alpha-papillomavirus. The most 
important of these are HPV 16, HPV 18 and 45. Papilloma viruses are epitheliotropic and 
predominantly infect skin and mucous membranes. These produce abnormal epithelial 
proliferations at the site of HPV infection. These benign epithelial proliferations or 
papillomas can undergo malignant transformation in certain circumstances. HPV 
infections occur on the skin, mucous membranes, oral cavity, conjunctiva, larynx, 
tracheobronchial tree, urinary bladder, esophagus, anus and genital tract. HPVs replicate 
only in the nucleus of infected cells(25).   
More than 40 types of HPV can infect the anogenital tract and based on their associations 
with anogenital and cervical cancers, 13 different anogenital HPVs have been identified 
and classified by the International Agency for Research on Cancer(IARC) as oncogenic. 
These include HPV 16, 18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59 and 66 (25).  HPV types 
68 and 82  are also considered oncogenic by few others(26).  HPV 6 and 11, which are 
the two types that are most commonly associated with condyloma acuminata, are not 
implicated in the development of cervical cancer. But they are associated with 
carcinomas of the larynx, vulva, penis and anus (25). 
 In LSIL, HPV 16 was found in 26% of HPV positive cases and 8% for HPV 18. HPV 31, 
51 and 53 were the other most commonly identified types in LSIL, each being present in 
approximately 10–12% of the lesions. Multiple HPV types are frequently found in low-
grade lesions. 
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In contrast to LSIL, more than half of HPV types are associated with HSIL.  Prevalence 
of HPV 16 in cases of HSIL, in studies from different regions from the globe range from 
30% to 70%(27). HPV types 16 and 18 were also found in 52% of the HSIL lesions. HPV 
31, 33, 58 and 52 are the other common types found in HSIL. Multiple types of HPV are 
less commonly found in HSIL than in LSIL.HPV types 16 and 18 are found in about 70% 
of invasive cervical cancers worldwide.  HPV types 31, 33, 35, and 45 are each found in 
approximately 3–4% of cervical cancers (27).  The other high-risk HPV types are found 
to be associated only with about 2.5% of cervical cancers and most are found in less than 
1%. 
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Genomic Organization of HPV: 
 
 
Fig 1: Pathogenesis of HPV in precancerous and cancerous cervical lesion 
 
Adapted from Woodman et al, Nat Rev Cancer 2007;7:11-22 
The genomic organization of different types of HPV appear to be similar. The viral 
genome has three different regions: an upstream regulatory region, the early region and 
the late region. The LCR is important for viral replication and transcription. The early 
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region is transcribed early in the viral life cycle and encodes proteins that are needed for 
viral replication. The late region encodes for viral structural proteins that are produced 
late in the life cycle. Open reading frames (ORFs) of early region encode proteins needed 
for viral replication and maintenance in infected cells. The early region of HPV genome 
contains E5, E6 and E7 transforming regions. The E6 and E7 ORFs encode the major 
transforming genes of HPV (28). E6 can bind to p53 and result in rapid proteolytic 
degradation of p53, through ubiquitin-dependent mechanism, thus preventing apoptosis. 
E7 binds to the retinoblastoma(Rb) gene product and also to ‘‘Rb-like proteins’’.  
Binding of E7 to Rb blocks the cell proliferation by inhibiting the function of these 
endogenous tumor suppressors. The final result of over expression of E6 and E7 within 
infected cells is unrestricted cell proliferation. 
 
The late region of HPV is downstream to the early region and contains L1 and L2 viral 
capsid proteins. The L1-encoded protein is the major capsid protein. The L2-encoded 
protein is a minor capsid protein that is much more variable among viral types. 
Transcription from the L1 and L2 ORFs occurs as a late event in the life cycle of virus at 
a time when infectious virus is being produced. Viral-like particles (VLPs)  composed of 
L1 capsid proteins have recently been introduced as prophylactic HPV vaccines(29). The 
initial site of infection is most likely the basal cells where the HPV virus reaches through 
breaks in the epithelium. Once the virus enters these cells, they can exist in two forms. 
The forms are non-productive and productive. The non-productive form is when the virus 
exists in the cell, but does not replicate and produce virions. It is also called as latent 
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infection. This latent infection does not produce characteristic morphological changes in 
the epithelial cell. They can only be detected by molecular testing. Productive viral 
infection occurs independent of host chromosomal DNA synthesis and results in 
replication of viral DNA in the cervical epithelium. The infected cervical epithelial cells 
move toward epithelial surface as they mature. Transcriptional factors produced by the 
epithelium stimulate the production of viral capsid protein. Viral associated effects of 
HPV produce characteristic cytological and histological changes seen in the cervical 
epithelial cells due to large amounts of virions. These viral-associated effects include 
nuclear atypia, multinucleation, acanthosis, cytoplasmic vacuolization and koilocytosis. 
 
Most HPV infections are transient in nature and usually they undergo clearance or may 
became persistent latent infection within one to two years of detection(30). Cell mediated 
immunity plays an important role in clearance or development of latent infection.  High 
risk HPV infection will get cleared much slower than low risk HPV infection. The 
majority of HPV infections undergo clearance or become latent within 1–2 years of 
detection. Clearance or development of latency is presumed to be mediated by cell-
mediated immunity. If the infection is persistent for 36 months, the chance of clearance 
of HPV infection reduces considerably. Hence, persistent high risk HPV infection for 
more than two years increases the risk to of progression to a high grade precursor cervical 
lesion or invasive cervical cancer(31).  
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Approximately, 10 % of high risk HPV infections will stay for more than two years.  In a 
few women, recurrent HPV infections can occur after the clearance of the previous 
infection.  There is strong association between immunodeficiency and detection of HPV 
in patients with HIV infection detected in one study(32). The above facts suggest that 
women who appear to have cleared the HPV infection continue to harbor low copy 
number of latent HPV in the epithelium. HPV has high prevalence in sexually active 
population. Prevalence of high risk HPV infection is high in late teens and drops with 
increasing age, in women with normal cervical cytology(33). High HPV prevalence is 
seen in less developed countries due to unknown reasons, but this may be related to poor 
personal hygiene, sexual practices and increase in burden of comorbid conditions in the 
general population.  
 
Only about one-third of high risk HPV DNA positive women will show abnormal 
cytology. The overall incidence of abnormal cervical cytology is approximately 25-50% 
within the first 2 years of infection. The risk of abnormal cytology further declines to 
baseline level in the general population within 4 years(34). Risk factor for HPV 
persistence and development of HSIL are not well identified but the type of HPV is 
important in subsequent development of high grade lesion. Cumulative risk for the 
development of HSIL in women with persistent infection for 3-5 years due to HPV 16 is 
approximately 40 %.  Multiple types of HPV infections increase the risk for HSIL. It may 
be due to the sum of the risks for each individual type (35).  
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Due to understanding of the pathogenesis in squamous intraepithelial lesion, researchers 
have proposed that LSIL is multicellular in origin whereas HSIL is unicellular in origin.  
LSIL develops within latently infected cervical epithelial cells and is linked with multiple 
types of HPV infection. HSIL is frequently aneuploid associated with a single type of 
HPV and may have integrated HPV DNA(36). Squamous intraepithelial lesions can be 
monoclonal or polyclonal. Low risk HPV types in LSIL are polyclonal whereas high risk 
HPV types in LSIL are monoclonal(37).  This shows that LSIL associated with low risk 
HPV types are biologically different from lesions identified as low grade by histology, 
but harbor high risk HPV types. Studies on CIN1 and CIN2 have shown that 83 % of 
monoclonal lesions progress and 64% polyclonal lesions regress(38).  
 
Cellular origin of squamous intraepithelial lesions: 
Three sites have been proposed as the site of origin of squamous intraepithelial lesions 
(SIL). They are basal cells of the squamous epithelium of the portio, basal cells of the 
transformation zone and reserve cells of endocervix(39). Transformation zone is the most 
common site for origin of SIL.  About 10% of SIL can occur in the endocervical canal 
without squamocolumnar junction involvement(40). So SIL involving exocervical 
surface is considered as low grade and SIL extending into endocervical canal is high 
grade.  From these observations, now it is proposed that most SIL arises in the basal cells 
of the transformation zone. In unscreened population, high grade cervical cancer 
precursors are more common than invasive cervical cancer. This suggests that only few 
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high grade precursors have the capacity to progress to invasive cervical cancers(41).  
Studies have shown that on long term follow up, partially treated or untreated HSIL had 
30-50 % chance for progression to invasive cervical cancer over 30 years(42).  
 
Clinical features: 
SIL is seen more commonly on the posterior lip of cervix and it involves rarely the lateral 
cervical regions(43). It may spread horizontally and involve the entire transformation 
zone. Rarely endocervical extension beyond the endocervical canal and then into the 
uterus can be seen. Based on the severity of the lesion, the size and endocervical 
distribution tend to vary. 
 
Screening tests: 
Pap smear: 
Even though pap smear is the best screening test and has reduced significant number of 
cervical cancer deaths, there are limitations. Sensitivity of one Pap smear to identify 
cervical intraepithelial lesions ranges from 30-87%(44). Approximately 30 % patients 
who are diagnosed with cervical cancer have at least one previously false negative Pap 
test.  
 
 
 
 
19 
 
Criteria for precancerous cervical lesion:  
According to the Bethesda 2014, squamous cell abnormalities are classified as  
following:(45) 
1) Atypical squamous cells 
o of undetermined significance (ASC-US) 
o cannot exclude HSIL (ASC-H) 
2) Low-grade squamous intraepithelial lesion (LSIL) 
3) High-grade squamous intraepithelial lesion (HSIL) 
4) Squamous cell carcinoma. 
 
 
Table 1: Criteria used to diagnose squamous cell abnormalities 
 
 
 
 
 
 
 
Adapted from Blaustein’s Pathology of the Female Genital Tract - Sixth Edition 
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Bethesda System subdivides the ASC category into two subdivisions.  
o Atypical squamous cells of undetermined significance (ASCUS) refers to samples in 
which the cytological changes are suggestive of LSIL, but lack sufficient cytological 
abnormalities to allow a definitive diagnosis.  
o Atypical squamous cells – cannot exclude HSIL (ASC-H) refers to samples in which 
the cytological changes are suggestive of HSIL but not insufficient to allow a 
definitive interpretation. 
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1. Atypical squamous cells of undetermined significance(ASC-US) 
Criteria: 
• In ASC-US cells nuclei are enlarged from 2.5to 3 times of the normal intermediate 
cell nucleus or more than 2 times the nucleus size of a squamous metaplastic cell.  
• Mildly increased N/C ratio with minimal nuclear hyperchromasia and irregularly 
distributed chromatin. 
•  Atypical parakeratosis and incomplete koilocytosis. 
 
2. Low grade squamous Intraepithelial lesion (LSIL)  
Criteria: 
• Nuclear enlargement > 3times of normal intermediate nuclei with mildly increased 
N/C ratio.  
•  Cytoplasmic and nuclear changes usually seen in intermediate or superficial 
squamous cells. 
• Overall cell size is enlarged with abundant cytoplasm. 
• Nuclei are usually hyperchromatic with coarsely granular to densely opaque 
chromatin, mild anisonucleosis and absent nucleoli. 
• Smooth to irregular nuclear membranes. 
• Cells with koilocytosis should also have nuclear abnormalities to be considered as 
LSIL.  
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Figure 2: Atypical squamous cell of undetermined significance at 200x 
ASC-US (LBP, thin prep) - Cohesive sheets of cells shows nuclear enlargement of more 
than two and half times of nucleus of intermediate cells. 
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Fig 3:  Low grade Squamous Intraepithelial Lesion(LSIL)at 400X 
LSIL (LBP, thin prep) -  Intermediate cells with koilocytic change with perinuclear halo, 
nuclear enlargement and few with nuclear membrane irregularity. 
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Atypical squamous cells – cannot exclude HSIL (ASC-H): 
Criteria:  
• Atypical squamous cells – cannot exclude HSIL (ASC-H) - cytological changes are 
suggestive of HSIL but not insufficient to allow a definitive interpretation. 
• Cells are size of metaplastic cells usually seen singly or arranged in small groups. 
• Nuclei about 1.5–2.5 times more than normal metaplastic squamous cells with high 
N/C ratio. 
High-Grade Squamous Intraepithelial Lesion (HSIL): 
Criteria: 
• HSIL cells are smaller and show less cytoplasmic maturity as compared to cells of 
LSIL but higher N/C ratio.  
• Cells occur singly, sheets, or in syncytial-like aggregates may result in 
hyperchromatic crowded groups.  
• Nuclei are generally hyperchromatic with irregular nuclear grooves and frequent 
indentation. 
• Nucleoli are usually not seen, but may be present when high grade lesion extends into 
endocervical gland.  
• Cytoplasm is usually immature but occasional “mature” and densely keratinized 
cytoplasm may be seen. 
 
25 
 
 
 
 
Figure 4: Atypical Squamous cell – Can not exclude HSIL (ASC-H) at 400x 
ASC-H (LBP, thin prep) -  A few metaplastic squamous cells with enlarged nuclei, high 
nuclear to cytoplasmic ratio, coarse chromatin and irregular nuclear contour.  
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Figure 5:  High grade squamous intraepithelial lesion (HSIL) at 400x 
HSIL (LBP, thin prep) -  Clusters of cells with high N/C ratios, fine granular chromatin, 
few with visible nucleoli and an occasional nuclear groove. 
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Management of precancerous cervical lesions: 
The American Society for Colposcopy and Cervical Pathology (ASCCP)guidelines(18):  
Atypical squamous Cells of Undetermined Significance: (ASC-US) 
• Women with ASC-US who are HPV-negative should come for repeat HPV testing or 
co-testing at 3 years. 
 
• Women with ASC-US who are HPV-positive should be referred for colposcopy 
examination to look for precancerous lesion. 
 
• If hr-HPV test is not available, suggested follow-up at 12 months. 
 
• If colposcopy is negative, co-testing is recommended at 12 months. If both tests are 
negative (Cytology as well as HPV), suggested follow up testing in 3 years. 
 
• Diagnostic excisional tests like loop electrosurgical excision is not acceptable in 
women with ASC-US cytology with absence of high grade (CIN2+) cervical 
intraepithelial lesion.  
 
• Follow-up of ASC-US in special populations: women aged 21–24 years, women aged 
65 years and older, pregnant women, and postmenopausal women. 
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Low-Grade Squamous Intraepithelial Lesion (LSIL) 
• ASCUS-LSIL Triage Study (ALTS) suggested that high-risk -HPV testing is not 
recommended particularly  in women with less than thirty years due to the high 
prevalence of HPV infection(46).  
 
• HPV testing is advisable for LSIL in postmenopausal women because of more 
specificity in this group of women.  
 
• HPV co-testing in women with LSIL cytology is recommended above 30 years of age. 
 
• Follow-up is recommended in women with LSIL cytology less than 25 years of age at 
the interval period of 12 months 
 
• In women above 25 years and older, co testing is recommended in 3 years, if HPV test 
result is negative, whereas colposcopic examination is suggested if HPV results is 
positive. 
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Atypical Squamous cells – Cannot exclude HSIL(ASC-H) 
• Colposcopy guided cervical examination is recommended for women with ASC-H 
cytology irrespective of HPV result.  Reflex HPV testing is not advisable in  
ASC-H cytology. 
 
High-Grade Squamous Intraepithelial Lesion (HSIL) 
• Colposcopy guided cervical examination is recommended for women with HSIL 
cytology. HPV testing is not recommended.  
 
• Most of the women with a cytologic result of HSIL will have identifiable lesion in 
colposcopy and  biopsy of lesion should be taken to confirm high grade (CIN 2+) 
cervical intraepithelial lesion(47).  
 
• Women aged 25 years and older with cytologic HSIL, immediate excisional 
procedure may be performed at the time of colposcopy if a lesion is identified. 
 
• If biopsy does not show high grade intraepithelial lesion (CIN 2+), review of cytology 
as well as histology slides are required. For difficult cases p16 
immunohistochemistry, may be helpful in identification of the lesion(48). 
 
 
30 
 
Treatment: 
Colposcopy with biopsy helps in planning the management of patients with precursor 
lesions of cervix. It allows the gynaecologist to rule out invasive cancer. These 
precancerous cervical lesions will be treated by conservative methods like laser ablation, 
cryosurgery and loop electrical excision procedure (LEEP) or cone biopsy. 
Prognosis: 
High grade precursor lesions are more likely to persist.  Approximately 57% of CIN 1 
lesions regress spontaneously without any intervention and 11% progress to carcinoma in 
situ. About 43% of CIN 2 lesions regress while 22% progress to carcinoma in situ.  32% 
of CIN III lesions regress and 12 % progress to carcinoma in situ(49). Recent studies by 
Castle et al. shows that rates of spontaneous regression of biopsy confirmed CIN II after 
24 months of follow-up was 43%  which is identical to older studies(50). 
HPV DNA testing. 
Because of known association between high risk HPV infection and cervical cancer, hr-
HPV DNA testing becomes a very important test in forming strategies for cervical cancer 
screening. Initially it was approved as a triage test which improved the detection of high 
grade cervical lesion in smears with minor cytological abnormalities compared with 
repeat cytology. Though, hr-HPV DNA test is useful to triage smears with minor 
cytological abnormalities, it has low specificity due to inability to differentiate between 
transformed HPV infection and transient HPV infection. The hr-HPV DNA testing can be 
done on liquid based cytological specimens. 
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Since the knowledge of HPV pathophysiology has been established, the identification of 
new biomarkers with ability to distinguish those at risk of disease progression becomes 
necessary. Therefore several host cell biomarkers were evaluated to improve the 
specificity for the screening of  cervical intraepithelial lesions(3).  One such bio marker 
which has been recently identified is dual P16INK4A/ki67.  
 
p16 INK4A:  
P16 INK4A (also referred to as p16) is a tumor suppressor protein that helps in cell cycle 
regulation. It acts by inhibiting cyclin D – cyclin dependent kinase 4 complex formation, 
thereby preventing cell cycle progression. Numerous studies have demonstrated p16 to be 
down regulated in many tumors. However, interestingly, increased expression of p16 has 
also been described in few tumors (51). 
 
Physiological role of p16Ink4a:   
P16 belongs to the Ink4 family of cyclin dependent kinase inhibitors. The CDKN2A gene 
encoding this protein is located on chromosome 9p21 within the INK4a/ARF locus.  This 
gene codes for two different proteins which inhibit cell cycle progression - p16Ink4a and 
p19ARF.  
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Fig 6: Molecular mechanism of cervical cancer by HPV 
 Adapted from Romagosa et al, Oncogene (2011) 
P16Ink4a is involved in the Retinoblastoma pathway (Rb), whereas p19ARF acts via the 
p53 pathway. These proteins act as tumor suppressor proteins by complex interactions. 
(52,53). Retinoblastoma (RB) protein is a crucial negative regulator of cell cycle 
progression from the G1 phase to S phase. Within quiescent cells, RB protein in its active 
hypo phosphorylated state complexes with E2F transcription factors that are required for 
the expression of genes which help in progression to S phase. This prevents G1-S 
transition and causes cell cycle arrest. However, when RB protein is phosphorylated by 
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cyclin D – cyclin dependent kinase 4/6 complex, it releases the E2F transcription factors, 
and thereby facilitates cell cycle progression.(53). P16Ink4a acts as a CDK inhibitor, 
blocks the cyclin D – CDK4/6 mediated phosphorylation of Rb and induces cell cycle 
arrest. In HPV-related neoplasms, the molecular mechanism if p16 INK4a can be 
explained by the presence of HPV oncoproteins E6 and E7. The integration of the viral 
DNA into host DNA causes overexpression of these viral oncoproteins. E6 protein binds 
and causes degradation of p53. E7 binds to RB protein and displaces the E2F 
transcription factors promoting cell cycle progression(54,55). This inactivation of the RB 
protein releases p16 INK4a from its negative feedback control, which in turn causes a 
paradoxical increase in the levels of p16. Therefore, the overexpression of p16 INK4a in 
HPV related tumors is considered to be due to an unsuccessful attempt to inhibit cell 
replication(56). In addition to its role in cell cycle regulation, p16 INK4a has also been 
implicated in  few other cellular processes including apoptosis, cell invasion and 
angiogenesis and it has been hypothesized that this role may contribute to its 
overexpression in some neoplasms(57). 
 
Subcellular location of p16Ink4a overexpression: 
Cell cycle regulation has been the classic function related to p16 INK4a and this 
characteristically take place in the nucleus. However, there is considerable recent 
evidence of significantly increased levels of p16 INK4a in several neoplasms and this has 
also been shown to be associated with tumor progression in few of them(58).  It has been 
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hypothesized that p16 INK4a has varied roles in varied subcellular locations, and that the 
nuclear p16 INK4a mainly regulates cell cycle. This has been supported by studies that 
show downregulation of nuclear p16 INK4a was associated with E2F overexpression. 
However, overexpression of cytoplasmic p16 INK4a exhibited no relation with E2F 
expression(59). Many theories have been postulated to explain the presence of 
cytoplasmic p16 INK4a, and it seems this is unrelated to p16 INK4a gene alteration. 
Proteomic and post translational studies have shown that p16 INK4a is expressed in 
different subcellular location, depending on post-translational modification or its ability 
to form complexes with other proteins(60). In quiescent cells, p16 INK4a forms a 
complex with CDK4 and prevents its subsequent kinase function. 
 The p16 INK4a/CDK4 complex is a large complex that is unable to pass through the 
nuclear membrane. However, in neoplastic cells, the localization of p16 INK4a in the 
cytoplasm due to CDK4 sequestration is considered to be an indirect effect of the RB 
pathway alteration. Anion exchanger protein 1 (AE1) is another transmembrane protein 
that causes sequestration of p16 INK4a in the cytoplasm with co-accumulation of both 
proteins. Also, p16 INK4a interacts with numerous cytoplasmic proteins, such as α-β-γ 
actin, α-β tubulin and CDK4/6(61). It is important to note that further work is still needed 
to elucidate the molecular mechanisms of p16 INK4a cytoplasmic localization and its 
connection with failure of the tumor suppressor function of p16 INK4a. 
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Adapted from Romagosa et al, Oncogene (2011) 
 
Figure 7: Molecular difference between expression of p16 and Ki-67 among 
different tumors. 
The role of p16 in different tumors is explained in the above picture. The first picture 
shows schwannoma with overexpression of p16, which is linked to the senescence 
induction due to the oncogenic stimuli, associated with low ki67 index. The second 
picture shows malignant peripheral nerve sheath tumor, with loss of p16 expression and 
associated with high ki67 proliferative index.  The third picture shows an undifferentiated 
sarcoma with overexpression of p16 as well as ki67 index, due to alteration in the Rb 
pathway(51). 
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Ki-67: 
Cell proliferation is strictly associated with high expression of ki-67 protein in human 
beings. This ki-67 antigen is exclusively identified within the nucleus during interphase 
but in mitosis majority of this antigen is seen over the surface of chromosomes. Hence in 
all active phases of cell cycle ki-67 protein is expressed (G1, S, G2 & mitosis).  Ki67 
protein is absent during resting phase(G0). So, it is used to calculate the growth fraction 
of cells.  Even though this ki-67 protein is well identified in molecular levels as good 
indicator of proliferation, functional characteristics still remains unclear.  Ki-67 protein 
expression is a must  for progression through the cell-division cycle(62). 
 
P16/ki-67 dual immunocytochemistry:  
p16 immunohistochemistry is used for identification of p16 overexpression in cervical 
biopsies which indicates oncogenic transformation caused by persistent hr-HV infections.  
However, in 2011 CINtec PLUS immunocytochemistry assay was introduced in cytology 
which provides simultaneous qualitative detection of p16 and Ki-67. P16 is the cyclin-
dependent kinase inhibitor. From the molecular pathogenesis, increased expression of 
p16 with activation of E2F is identified as a response to incorporation of HPV E7 
oncoprotein with RB gene. Ki-67 is used as proliferative index for assessment of growth 
fraction of cell cycle. Combining p16 with ki-67, detects the HPV infected cells 
undergoing transformed and uncontrolled proliferation. 
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There are several studies  done on the performance of dual immunocytochemistry for p16 
and Ki-67 for the identification of CIN2+ lesion(63–67). Bergeron et al assessed 
performance of P16/Ki-67 dual immunocytochemistry in a group of 28,000 women,  
from 5 European countries.  In that study, performance of hr-HPV test and p16/Ki-67 
dual immunocytochemistry were compared among women with the diagnosis of ASCUS 
and LSIL.  Sensitivity of p16/Ki-67 in ASCUS for the detection of CIN II+ was 92.2% 
(90.9% for HR HPV test), specificity was 80.6% (36.3% for HPV test). In a group of 
LSIL, sensitivity was 94.2% (96.4% for hr-HPV test), specificity was 68.0% (19.1% for 
hr- HPV).  
 
Petry et al performed the utility of p16/Ki-67 dual immunocytochemistry for the 
detection of CIN II+ lesions in women with hr-HPV positive tests. p16/Ki67 showed 
sensitivity of 91.9% for CIN II+ and specificity was 82.1% for CIN II. Wentzensen et al 
compared the results of p16/Ki67 immunocytochemistry with high risk HPV test in 
identification of CIN II+ lesions in colposcopy referral population. Sensitivity was 85.5% 
and specificity 59.4% for CIN II whereas for CIN III sensitivity was 90.6% and 
specificity was 48.6%. These studies showed that specificity of dual 
immunocytochemistry is higher as compared to hr-HPV test, in detection of underlying 
high grade cervical intraepithelial lesion. Hence, p16/ki-67 can be used as a triage tool for 
minor cytological abnormalities i.e. low grade squamous intraepithelial lesion(LSIL) and 
atypical cells of undetermined significance (ASC-US).  
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In all the above studies co-expression of cytoplasmic p16 and nuclear Ki-67 in at least 
one cell was considered as positive ICC test which indicates transformed infection. The 
concept of single positive cell as a cutoff has been used due to the monoclonal nature of 
any malignant neoplasm. But these studies also showed that false positivity for p16/Ki-67 
resulted in decrease in its positive predictive value to identify underlying high-grade 
lesion. 
 
According to recent literature by Peter Zeimke, when a higher cut off of 10 cells was 
used, the probability of underlying high-grade lesions (CIN2+) also increased in a 
sample. Using a score of 10 cells as a positive result instead of 1 cell led to significantly 
improved specificity (89 vs 70.2%) and positive predictive value(55.7%vs 46.7%) among 
women in LSIL group(68). Interpretation of p16/Ki-67 dual immunocytochemistry is 
morphology independent: thus, limited training is needed for interpretation and also this 
test has good reproducibility. A few studies have evaluated the performance of p16/Ki-67 
in urine cytology also.  P16 over expression in urothelial carcinoma is independent of 
high-risk HPV oncoprotein. In urothelial carcinoma p16 expression is most often 
undetectable. It is due to either deletion or mutation of CDKN2A. In contrast, over 
expression of p16 has been reported in urothelial lesions up to 80% of high grade tumors 
and 100% of carcinoma in situ cases. It may be due to mutation of E2F transcription 
factor gene or alteration of Rb gene, resulted in phosphorylation of the Rb protein and 
uncontrolled progression of the cell cycle. p16 overexpression indicates aggressive 
disease and may be used for prognostic and therapeutic purpose. 
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Clinical utility of p16/ki-67 in urothelial malignancies has also been assessed in a few 
studies. These studies propose that dual immunocytochemistry is used in evaluation of 
high grade urothelial cancer and for the follow-up management after conservative 
treatment for non- invasive urothelial carcinoma (69,70). 
 
The purpose of this study is to assess the significance of p16/ki67immunocytochemistry 
in improving the predictive value for high grade cervical intraepithelial CIN2+lesions. 
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MATERIALS AND 
METHODOLOGY 
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After approval from the Institutional Review Board (IRB) min no: 10175, this prospective 
diagnostic study was conducted in the Department of Pathology, in conjunction with Department 
of Virology and Department of Gynaecologic oncology. 
 
Study population: 
A total of 175 patients from gynecology/ gynecologic oncology, whose cervical smears 
were reported by the Department of general pathology as ASC-US/LSIL/ASC-H and 
HSIL, were identified for the study, over a period of 8 months from August 2016 to 
March 2017.  Information sheet and consent form were given to all patients willing to 
participate in this study.  
 
Exclusion criteria:  
All patients, who were 
• Less than 25 years, 
• Pregnant women,  
• Patients unwilling for colposcopy/ biopsy, 
• Seropositive patients and  
• Patients previously treated for CIN were excluded from this study. 
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Study design 
 
  
 
 
 
 
 
 
 
 
 
Figure 08: Detailed diagrammatic Algorithm of the study. 
 
 
 
All sexually active women >25 years who come to gynecology OPD 
 
Cervical cytology screening by thin prep Negative 
positive (ASC-US/LSIL/ASC-H/HSIL) Excluded 
from study 
the study 
Hr-HPV DNA test  
 
 
Colposcopy p16/Ki67 on pap smears 
Positive Negative Biopsy Positive Negative 
43 
 
Sample collection and processing:  
Thin prep cervical smear: 
The residual Thin prep sample material of all study patients (Hologic vials) were stored at 
2-4 degree Celsius for up to 6 weeks. If the samples exceeded 6 weeks of storage period, 
they were processed in the Thin Prep® 2000 Processor (Hologic™ Inc.) and the 
unstained smears were stored in ethanol fixative at 2-4degree Celsius.  
The dual immunocytochemistry was performed in batches. In view of inadequacy and 
poor cellularity of some smears that were stored, the third batch of smears were prepared 
from the refrigerated samples, on the day of the ICC procedure. 
Technical procedure as described in Appendix-1. 
P16/ki67 dual immunocytochemistry: 
Immunocytochemistry analysis using the CINtec PLUS Cytology kit (Roche MTM 
Laboratories, Heidelberg, Germany) were done on these smears according to the 
manufacturer's instructions.  All slides were examined by the principal investigator and 
the guide. 
Technical procedure as described in Appendix-2. 
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Hr-HPV DNA test: 
HPV DNA tests for hr-HPV were also done on all study patients as per the standard 
management protocol followed in the Gynecology outpatient department. The material 
for this test was collected at the time of colposcopy in using the digene HC2 DNA 
collection device which consisted of a cervical brush and digene Specimen Transport 
Medium(STM).  In vitro nucleic acid assay with signal amplification by Hybrid Capture 
2 assay (HC2; Digene Corp., Gaithersburg, MD) was used. 
Technical procedure as described in Appendix-3. 
Interpretation of HPV DNA:       
  The hr - HPV DNA data was interpreted based on the results (positive/ negative) 
obtained from Hybrid Capture (HC2) in the department of virology. Serial amplification 
assay for hr- HPV DNA in cervical specimen can detect upto13 different hr-HPV DNA 
types [16,18,31,33,35,39, 45,51,52,56,58,59 and 68] in the cervical cells. Detection of hr-
HPV DNA in Hybrid Capture (HC2) technique is done by using microplate 
chemiluminescence. The result is obtained as relative light units (RLU). The digene 
analysis hr-HPV DNA test cut off of 1 pg/ml is equivalent to 1,00,0000 HPV copies /ml 
or 5,000 copies per assay. STM (Specimen Transport Medium) specimen with 
RLU/cutoff Value ratios equal or greater than 1 are considered ‘positive’. Specimens 
with RLU/cutoff value ratios<1 considered ‘Negative’ or ‘None detected’ for the 13 HPV 
types tested. 
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Colposcopy and biopsy:  
Colposcopy and biopsy were also done on all the study patients as part of a routine 
protocol, in the Gynecology outpatient department, according to accepted diagnostic 
standards. 
Histopathology: 
Fixed tissue samples were processed to paraffin blocks in the histopathological 
laboratory. Slides(4μm) were cut on the microtome, stained with hematoxylin and eosin 
(H+E) and were assessed by histopathologists who were blinded to the ICC and HPV 
results of the study patients.  Biopsy was considered as gold standard, against which the 
new dual immunocytochemistry and hr-HPV DNA results were correlated. 
Interpretation of P16/ki-67 dual immunocytochemistry: 
The dual immunocytochemistry was interpreted by the primary investigator and guide. 
The presence of one or more cervical epithelial cells with co-localization of brown 
cytoplasmic immunostaining and red nuclear immuno-staining within the same cell was 
regarded as a positive CINtec PLUS test result. We also assessed the performance of  
p16/Ki-67 dual immunocytochemistry, with a cut off for positivity as more than ten  
cells.  
If there is no cervical epithelial cell showing simultaneous brown cytoplasmic immuno 
staining and red nuclear immuno-staining, the CINtec PLUS test result is considered 
negative.  
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The presence of cervical epithelial cells that do show a single immuno-reactivity only for  
one of the two markers (e.g. – Brown staining for p16 only, or red staining for Ki-67 
only) 
 is not considered as a positive test result for the CINtec PLUS kit. Strict criteria for 
positive and negative tests were followed to avoid discrepancy. 
 
Smears from a known case of squamous cell carcinoma were used as a positive control, 
with colocalization of both brown cytoplasmic immunostaining (p16) and red nuclear 
immunostaining (ki67). Different cell types present in representative cervical cytology 
specimens, that are known to be negative for the expression of the p16 and ki-67 antigens 
(such as superficial cells) may serve as an additional internal negative control to assess 
any background staining.  
 
Clinical details of the cases: 
The clinical details of these patients were obtained from the charts retrieved from the 
Medical Records Department. The clinical features that were analyzed include age, 
indication for cervical screening, marital status, parity and menopause status. 
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Statistical method used 
Sample size calculation: 
The required samples size to show sensitivity of about 90% with 10% precision and 95% 
confidence interval was found to be 35 patients. 
Clinical Research form: 
The data obtained from each test and the necessary clinical information obtained from the 
clinical workstation were entered into the clinical research form for each case. (Form 
attached in annexure). 
Data entry and analysis:   
Data entry and analysis was done with Epidata software. Statistical analysis was 
performed by SPSS ststistics16.0 (statistical Package for Social Sciences, Version 16.0).  
Diagnostic statistics were used to assess the performance of the hr- HPV DNA test and 
p16/ki-67 dual immunocytochemistry. The sensitivity, specificity, positive and negative 
predictive values were calculated with corresponding 95% confidence intervals. To 
assess the statistical significance, we used P value as well as 95% CI difference in 
sensitivity, specificity, positive predictive value and negative predictive value between 
the tests. P value <0.05 was considered as statistically significant. Similarly, if 95% CI 
difference range does not include zero, it is considered statistical as well as clinically 
significant and if it has zero it was considered statistically not significant. Cohen’s kappa 
agreement coefficient was used to compare the above two tests. Kappa values between 
0.40 and 0.60 were considered to be moderate and those between 0.60 and 0.80 as good. 
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RESULTS 
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                                            Study flow chart 
 
Total number of study samples: 175 
 
Lost to follow up =32 
Biopsy not done = 11 
HPV test not done = 08 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Selection of cases included under study 
 
Total samples available for testing: 124 
 
Adequate  
 
 
Scanty 
 
Inadequate(excluded) 
 
76 
 
 
 
 
18 
 
30 
Total study cases: 94 
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A total of 175 cases were reported as ASCUS, LSIL, ASC-H and HSIL between August 
2016 to March 2017.  Thirty-two patients did not come for follow -up, eleven cases did 
not have biopsy and eight cases did not have HPV. Fifty-six cases were excluded from 
the study, leaving a total of 124 samples for further testing.  
 
 All slides were kept in 100% ethyl alcohol fixatives and stored in 2-3 degree Celsius.  
All tests were done in three batches in different time periods.  Among 124 samples only 
76 cases had adequate cellularity, 18 cases were paucicellular. Thirty cases did not have 
enough material to process, hence were excluded from the study, leaving a total of 94 
women for inclusion in the study. 
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ABNORMAL PAP SMEAR GROUPS: 
 
 
Figure 10: Number of cases in each abnormal pap smear groups 
 
The median age was 42.73 years (standard deviation of 11.4 years) for overall abnormal 
pap smears with ASC-US, LSIL, ASC-H and HSIL. The youngest woman was 24 and the 
oldest patient was 71. 
• ASC-US: 43 (45%) 
• LSIL: 16 (17%) 
• ASC-H: 14 (15%) 
• HSIL: 22 (23%) 
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Figure 11: Different groups in accordance with age 
 
ASC-US was the most common intra epithelial lesion identified in all age group of 
women.  
 
There were 12cases (13%) less than 30 years of age and 82 cases (87%) above 30 years 
of age.  
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SCREENING:  
 
 
 
Figure 12:  Indication for screening 
 
Among 94 women, 75 were symptomatic (80%) whereas 19 were asymptomatic (20%) 
who were referred for routine screening. 
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SYMPTOMS: 
 
 
 
Figure 13: Different clinical presentation of abnormal pap smears 
 
Symptomatic women presented with following complaints: 
Bleeding per vagina (59%), lower abdominal pain (16%), white discharge per vagina 
(11%), itching (7%), burning micturition (4%), post coital bleeding (3%) and cervical 
growth (1%). Bleeding per vagina was the most common clinical presentation of women 
presented to gynecology/ gynecologic oncology. 
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MENSTRUAL STATUS: 
 
 
 
 
Fig 14:   Number of reproductive and postmenopausal women 
 
Among 94 women, 25 were in postmenopausal age group (27%) and 69 were 
reproductive age group (73%).   
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Hr-HPV TEST vs BIOPSY IN ≥ CIN2 LESIONS: 
 
Table 02: hr– HPV test vs biopsy in ≥ CIN 2 lesions cross tabulation:  
The above table shows performance of hr-HPV test among abnormal Pap smears as 
compared with the gold standard of ≥ CIN2 lesions i.e. biopsy. There were 94 study 
cases. Hr-HPV test was positive in 58 cases and negative in 36 cases. Among positive 
cases 30 cases (32%) had ≥ CIN2 lesions (True positive) and 28cases (30%) biopsies 
were negative (False positive). Among hr-HPV test negative cases, 1 case (1%) had ≥ 
CIN2 lesion (False negative) and 35 cases (37%) were negative (True negative) on 
biopsy. 
• Total number of cases: 94 
• Number of true positive: 30 (32%) 
• Number of false positive:28 (30%) 
• Number of false negative: 01 (1%) 
• Number of true negative: 35 (37%) 
 
≥ CIN2 LESIONS 
TOTAL 
 Positive Negative 
hr-HPV test 
Positive 30 28 58 
Negative 1 35 36 
TOTAL  31 63 94 
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P16/Ki-67 IMMUNOCYTOCHEMISTRY vs BIOPSY IN ≥ CIN2 LESIONS: 
 
Table 03: p16/Ki-67 vs biopsy in ≥ CIN2 lesions cross tabulation 
The above table shows the performance of dual immunocytochemistry test among 
abnormal Pap smears as compared with gold standard of ≥ CIN2 lesions i.e. biopsy. 
There were 94 study cases. Dual immunocytochemistry was positive in 49 cases and 
negative in 45 cases. Among positive cases 30 cases (32%) had ≥ CIN2 lesion (True 
positive) and 19 cases (20%) biopsies were negative (False positive). Among negative 
cases 1case (1%) had ≥ CIN 2 lesions (False negative) and 44 cases (47%) biopsies were 
negative (True negative). 
▪ Total number of cases: 94 
▪ Number of true positive: 30 (32%) 
▪ Number of false positive: 19 (20%) 
▪ Number of false negative: 1(1%) 
▪ Number of true negative:44 (47%) 
 
≥ CIN2 LESIONS 
TOTAL 
Positive Negative 
p16/Ki-67 
Positive 30 19 49 
Negative 1 44 45 
TOTAL  31 63 94 
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PERFORMANCE OF P16/KI-67 AND HR-HPV TEST IN DETECTION OF 
≥ CIN2 LESIONS: 
 
Table 04:  p16/Ki-67 and Hr-HPV test in ≥ CIN 2 lesions  
 
This table summarizes the analysis for sensitivity, specificity, PPV and NPV with gold 
standard ≥ CIN2 lesions for p16/Ki-67 and hr-HPV tests for abnormal Pap cases. The 
sensitivity of dual-stained cytology and hr-HPV DNA testing was 96.8% for ≥ CIN2 in 
all abnormal groups.  The specificity of dual-stained cytology was 70.2% for whereas hr-
HPV test had specificity of 55.8% (table 04).  
 Sensitivity 
%(95%CI) 
Specificity 
%(95%CI) 
PPV 
%(95%CI) 
NPV 
%(95%CI) 
Hr-HPV test 96.8  
 
55.8  
 
51.7  97.6  
 
P16/Ki-67≥ 1 
positive cell 
96.8 
 
70.2  61. 97.6  
 
P value 
 
1.00 
 
0.095 
 
0.324 
 
1.00 
 
95% CI 
Difference 
 
 
-09 to 09 
 
-02 to 31 
 
 
-09 to 28 
 
 
-06 to 06 
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Specificity for dual stained cytology was higher than hr-HPV test. The positive predictive 
value for dual stained cytology was 61.2% whereas hr-HPV test had 51.7%. The positive 
predictive value for dual stained cytology was higher than hr-HPV test. The negative 
predictive value for dual stained cytology and hr-HPV was similar 97.6%. P value and 
95% CI difference for both tests were not significantly significant (table 04). 
 
PERFORMANCE OF P16/KI-67 AND HR-HPV IN DETECTION OF ≥ CIN3 
LESIONS: 
 
 
Table 05:   p16/Ki-67 and Hr-HPV test in≥ CIN 3 lesions 
 
Sensitivity 
%(95%CI) 
Specificity 
%(95%CI) 
PPV 
%(95%CI) 
NPV 
%(95%CI) 
 
Hr-HPV test 
 
100  
 
47.4  
 
31  
 
 
100 
 
P16/Ki-67 ≥ 1 
positive cell  
 
100 
 
 
59.2  
 
36.7 
 
 
100  
 
P value 
 
1.000 
 
0.186 
 
0.534 
 
1.000 
 
95% CI  
Difference 
 
-14 to 14 
 
-29 to 05 
 
-12 to 03 
 
-13 to 13 
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This table summarizes the analysis for sensitivity, specificity, PPV and NPV with gold 
standard ≥ CIN3 lesions for p16/Ki-67 and hr-HPV tests for abnormal Pap cases. The 
sensitivity and negative predictive value for p16/Ki-67 dual immunocytochemistry and 
high-risk HPV test was 100% for ≥ CIN3 lesions. Specificity of p16/Ki-67 was 59.2 % 
and specificity of high risk HPV test was 47.4 %. 
 
 The positive predictive value for dual immunocytochemistry was 36.7 % whereas 28.6% 
for hr-HPV test. The specificity and positive predictive value of dual stained cytology 
were slightly higher than that of hr-HPV test. P value and 95% CI difference for both 
tests were not significantly significant (table 05). 
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THRESHOLD FOR POSITIVE IMMUNOCYTOCEMISTRY IN≥ CIN2 
LESIONS: 
The presence of one or more cervical epithelial cells with co expression of brown 
cytoplasmic P16 immunostaining and red nuclear Ki-67 immunostaining within the same 
cell is regarded as a positive CINtec PLUS test result. However, we also looked at 
performance of dual immunocytochemistry with a threshold of positivity for more than 
10 cells(68). 
 
Figure 15: Performance of p16/Ki-67 immunocytochemistry with different 
thresholds in detection of ≥CIN2 lesions 
Increase in threshold showed higher specificity (95.1 vs 70.2) and positive predictive 
value (89.3 vs 61.2) but there was decrease in sensitivity (78.1 vs 96.8) and negative 
predictive value (89.2 vs97.6). 
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Table 06:  p16/Ki-67(≥10 cells) and Hr-HPV test in≥ CIN 2 lesions 
This table summarizes the statistical difference for sensitivity, specificity, PPV and NPV. 
P value and 95% CI for sensitivity, specificity and positive predictive values were 
statistically significant. Negative predictive value was not statistically significant (table 
06). 
 
 
 Sensitivity 
%(95%CI) 
Specificity 
%(95%CI) 
PPV 
%(95%CI) 
NPV% 
(95%CI) 
Hr-HPV test 
 
96.8 55.8 51.7 97.6 
P16/Ki-67≥ 10 
positive cells 
78.1 95.1 89.3 89.2 
P value 0.026 <0.001 0.001 0.132 
95% CI 
difference 
2 to 34 25 to 52 20 to 54 -07 to 17 
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THRESHOLD FOR POSITIVE IMMUNOCYTOCEMISTRY IN ≥CIN3+ 
LESION: 
The diagnostic capability of dual stained cytology for ≥ CIN 3 lesions with positivity for 
more than 10 cells showed higher specificity (82.7 vs 59.2) and higher positive predictive 
value (53.6 vs 36.7) but there was decrease in sensitivity (83.8 vs 100) and negative 
predictive value (100 vs 95.4). 
 
Figure 16: Performance of p16/Ki-67 immunocytochemistry with different 
thresholds in detection of ≥ CIN3 lesions 
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Table 07: p16/Ki-67 (≥10 cells) and Hr-HPV test in ≥ CIN 3 lesions 
 
This table summarizes the analysis for sensitivity, specificity, PPV and NPV.  P value 
and 95% CI for sensitivity, specificity and negative predictive values were statistically 
significant. Positive predictive value was not statistically significant (table 07). 
 
 
 
 
 
 
 Sensitivity 
%(95%CI) 
Specificity 
%(95%CI) 
PPV 
%(95%CI) 
NPV 
%(95%CI) 
 
Hr-HPV 100 47.3 31 100 
P16/Ki-67≥ 10 
positive cells 
83.8 82.7 53.6 95.4 
 P value <0.001 <0.001 0.051 <0.001 
95% CI  
difference 
57 to 90 19 to 50 00 to 45 75 to 93 
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PERFORMANCE OF P16/KI-67 AND HR-HPV TEST IN DETECTION OF 
 ≥ CIN2 LESIONS IN WOMEN <30 YEARS:  
Table 08:  p16/Ki-67 and Hr-HPV test in ≥CIN 2 lesions in women <30 years 
This table summarizes the analysis for sensitivity, specificity, PPV and NPV with gold 
standard ≥ CIN2 lesions for p16/Ki-67 and hr-HPV tests for abnormal Pap cases in 
women < 30 years. There were 12 women less than 30 years of age and 82 women more 
than 30 years of age. The sensitivity and negative predictive values of hr-HPV and dual 
stained cytology were similar 100%. The specificity of hr-HPV was 45.5% and positive 
predictive value 12.1%. Sensitivity, specificity and negative predictive value and positive 
predictive value 95% CI difference and P value were not statistically significant (table 
08). 
 Sensitivity 
%(95%CI) 
Specificity 
%(95%CI) 
PPV 
%(95%CI) 
NPV 
%(95%CI) 
Hr-HPV test 100 45.5 12.1 100 
P16/Ki-67 ≥1 
positive cell  
100 36.4 14.3 100 
P value 1.000 0.301 0.737 1.000 
95% CI  
difference  
-14 to 14 -26 to 08 -10 to 15 -13 to 13 
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Figure 17: Performance of p16/Ki-67 immunocytochemistry with different 
thresholds to detect ≥ CIN2 lesions in women <30 years 
The dual immunocytochemistry showed, specificity of 36.4% and positive predictive 
value of 14.3% when a score of one or more cells was the positive threshold.  Both tests 
had low specificity and positive predictive value.  When the threshold was increased to 
more than ten cells there was significant increase in specificity (90 vs 30.6) and positive 
predictive value (50 vs 14.3). P value and 95% CI for specificity and positive predictive 
value were statistically significant. Sensitivity and negative predictive values were not 
statistically significant (table 09). 
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PERFORMANCE OF P16/KI-67 AND HR-HPV TEST IN DETECTION OF ≥ 
CIN2 LESIONS IN WOMEN LESS THAN 30 YEARS. 
 
Table: 09: p16/Ki-67(≥10 cells) and Hr-HPV test in ≥ CIN 2 lesions in women <30 
years 
 
This table summarizes the analysis for sensitivity, specificity, PPV and NPV.  P value 
and 95% CI for specificity and positive predictive values were statistically significant. 
sensitivity and negative predictive value was not statistically significant. 
 
 
 Sensitivity 
%(95%CI) 
Specificity 
%(95%CI) 
PPV 
%(95%CI) 
NPV 
%(95%CI) 
Hr-HPV test 100 45.5 12.1 100 
P16/Ki-67 >10   
positive cells 
100 90 50 100 
 
P value 1.000 <0.001 <0.001 1.000 
95% CI 
Difference 
-14 to 14 30 to 58 17 to 58 -10 to 10 
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PERFORMANCE OF P16/KI-67 AND HR-HPV TEST IN DETECTION OF ≥ 
CIN2 LESIONS IN WOMEN MORE THAN 30 YEARS. 
 
 
Table10: P16/KI-67 and hr-HPV test in ≥ CIN2 lesions in women >30 years 
 
This table summarizes the analysis for sensitivity, specificity, PPV and NPV for ≥ CIN2 
lesions p16/Ki-67 immunocytochemistry and hr-HPV tests for women >30 years. The 
sensitivity of hr-HPV test and dual immunocytochemistry cytology were similar 100% in 
all 82 women >30 years of age.  The negative predictive values of both hr-HPV test and 
dual stained cytology were relatively high (93.5 and 95.1). The specificity and positive 
predictive value for hr-HPV test were 56.9%. P value and 95% CI difference for 
specificity was statistically significant. Sensitivity, positive and negative predictive 
values were not statistically significant (table 10). 
 
Sensitivity 
%(95%CI) 
Specificity 
%(95%CI) 
PPV 
%(95%CI) 
NPV 
%(95%CI) 
Hr-HPV test 93.5 56.9 56.9 93.5 
P16/Ki-67≥ 1 positive 
cell 
93.5 76.5 70.7 95.1 
P value 1.000 0.020 0.140 0.756 
95% CI difference  -12 to 12 03 to 35 -04 to 31 -08 to11 
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Figure 17: Performance of p16/Ki-67 immunocytochemistry with different 
thresholds to detect ≥ CIN2 lesions in women >30 years 
The dual stained cytology showed, specificity of 76.5% and positive predictive value of 
70.7% when the threshold was taken as ≥ 1 cell.  When the threshold was more than ten 
cells, there was increase in specificity (96.1 vs 76.5) and positive predictive value (92.3vs 
70.7). 
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Table 11: P16/KI-67 (≥ 10 cells) and hr-HPV test in ≥ CIN2 lesions in women >30 
years 
This table summarizes the analysis for sensitivity, specificity, PPV and NPV.  P value 
and 95% CI difference for specificity and positive predictive value were statistically 
significant. Sensitivity and negative predictive value was not statistically significant 
(table:11). 
 
 
 
 
 Sensitivity 
%(95%CI) 
Specificity 
%(95%CI) 
PPV 
%(95%CI) 
NPV 
%(95%CI) 
Hr-HPV 93.5 56.9 56.9 93.5 
P16/Ki-67≥10 
positive cells 
77.4 96.1 92.3 87.5 
 
 P value 0.072 <0.001 0.001 0.342 
 95% CI  
difference 
-33 to 01 26 to 52 19 to 51 -17 to 53 
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AGREEMENT BETWEEN HR-HPV TEST AND P16/KI-67: 
 
The kappa for hr-HPV test to detect ≥ CIN2 lesions was 0.406. When > 1 cell was used 
as the threshold, the kappa was 0.559 but the agreement was increased to 0.754, when 
more than 10 cells were used as the threshold.  Thus, the kappa agreement for dual 
immunocytochemistry for ≥ CIN2 lesions was higher when compared to hr-HPV test.   
 
Figure 18: Agreement between p16/Ki-67 and hr-HPV test ≥ CIN2 lesions with 
different thresholds. 
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PERFORMANCE OF P16/KI-67 AND HR-HPV TEST IN DETECTION OF 
≥ CIN2 LESIONS IN ASC-US. 
Table 12:  p16/Ki-67 and hr-HPV in CIN ≥ 2 lesions for ASC-US 
This table summarizes the analysis for sensitivity, specificity, PPV and NPV with gold 
standard ≥ CIN2 lesions for ASC-US group. Sensitivity and negative predictive value for 
p16/Ki-67 dual immunocytochemistry and hr-HPV test were similar (100%) to detect 
high grade lesions among ASCUS group. P16/Ki-67 specificity was 82 % and positive 
predictive value was 30%. Hr-HPV test specificity was 71.8% and positive predictive 
value was 21.4%.  P value and 95% CI difference for both tests were not significantly 
significant (table 12).  
 Sensitivity 
%(95%CI) 
Specificity 
%(95%CI) 
PPV        
%95%CI) 
NPV 
%(95%CI) 
 
Hr-HPV test 
 
100 71.8 21.4 100 
P16/Ki-67≥ 1  
Positive cell 
 
100 82.1 30 100 
P value 
 
1.000 0.280 0.631 1.000 
95% CI  
difference 
 
-48 to 48 -08 to 28 -27 to 44 -15 to 15 
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Figure 19: Performance of p16/Ki-67 immunocytochemistry with different 
thresholds to detect ≥ CIN2 lesions in ASC-US. 
When the threshold was more than ten cells, there was increase in specificity (82.1 vs 
94.9) and positive predictive value (30 vs 50) and decrease in sensitivity (100 vs 66.7) 
and negative predictive value (100 vs 97.4). Sensitivity, specificity and positive 
predictive value P value and 95% CI were not statistically significant. Negative 
predictive value was not statistically significant (table:13) 
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Table 13:  p16/Ki-67(≥ 10 cells) and hr-HPV in CIN ≥ 2 lesions for ASC-US 
 
This table summarizes the analysis for sensitivity, specificity, PPV and NPV.  P value 
and 95% CI difference for specificity was statistically significant. Sensitivity positive 
predictive value and negative predictive value were not statistically significant (table:13) 
 
 
 
 
 
 Sensitivity 
%(95%CI) 
Specificity 
%(95%CI) 
PPV 
%(95%CI) 
NPV 
%(95%CI) 
 
Hr-HPV test 
 
100 71.8 21.4 100 
P16/Ki-67 ≥ 10 
 positive cells 
 
66.7 94.9 50 97.4 
P value 
 
0.185 0.006 0.260 <0.001 
95% CI  
difference 
 
-16 to 30 07 to 38 -24 to 82 75 to 99 
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PERFORMANCE OF P16/KI-67 AND HR-HPV IN DETECTION OF ≥ CIN2 
LESIONS IN LSIL: 
 
Table 14:  p16/Ki-67 and hr-HPV test in ≥ CIN2 lesions for LSIL 
This table summarizes the analysis for sensitivity, specificity, PPV and NPV with gold 
standard ≥ CIN2 lesions for LSIL group. Sensitivity and Negative Predictive Value for 
p16/Ki-67 dual immunocytochemistry and hr-HPV test were similar (100%) to detect 
high grade lesions among LSIL group. P16/Ki-67 specificity was 64.3 % and positive 
predictive value was 28.6%. Hr-HPV test specificity was 21.4% and positive predictive 
value was 8.3%. P value and 95% CI difference for sensitivity, specificity, PPV and NPV 
values were not statistically significant. (table:14) 
 Sensitivity 
%(95%CI) 
Specificity 
%(95%CI) 
PPV 
%(95%CI) 
NPV 
%(95%CI) 
 
Hr-HPV test 
 
 
100 21.4 8.3 100 
P16/Ki-67≥ 1  
positive cell 
 
100 64.3 28.6 100 
P value 
 
1.000 0.184 
 
0.242 1.000 
95% CI difference  
 
-58 to 58 -15 to 31 -16 to 57 -35 to 35 
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Figure 20: Performance of p16/Ki-67 immunocytochemistry with different 
thresholds to detect ≥ CIN2 lesions in LSIL. 
 
When the threshold was more than ten cells, there was increase in specificity (64.3 vs 
100) and positive predictive value (28.6 vs 100) and similar in sensitivity (100) and 
negative predictive value (100).  
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Table 15: p16/Ki-67(≥ 10 cells) and hr-HPV in CIN ≥ 2 lesions for in LSIL. 
 
This table summarizes the analysis for sensitivity, specificity, PPV and NPV.  P value 
and 95% CI difference for sensitivity, specificity, PPV and NPV values were not 
statistically significant. 
 
 
 
 
 
 Sensitivity 
%(95%CI) 
Specificity 
%(95%CI) 
PPV 
%(95%CI) 
NPV 
%(95%CI) 
Hr-HPV test 
 
100 21.4 8.3 100 
P16/Ki-67 ≥ 10             
positive cells 
 
100 100 100 100 
P value 
 
1.000 0.407 0.937 1.000 
95% CI  
difference 
 
-58 to 58 -15 to 38 -42 to 46 -33 to 33 
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MENOPAUSE STATUS: 
There were 25 women in postmenopausal age group. The sensitivity and negative 
predictive value for hr-HPV test and dual stained cytology were similar 100%. The 
specificity for hr-HPV test was 58.3 and PPV was 72.5. Dual stained cytology had 
specificity of 66.7% and PPV 76.5% when cutoff was one or more cells but with cutoff of 
more than 10 cells showed 100 % specificity and PPV for ≥ CIN2 lesions. 
 
 
Figure 18:  Performance of p16/Ki-67 immunocytochemistry and hr-HPV test to 
detect ≥ CIN2 lesions in postmenopausal women. 
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There were 69 women in reproductive age group.  The sensitivity for both tests were 
similar (89%). The negative predictive value for hr-HPV test was 93.1 and p16/Ki-67 
was 94.6%. The specificity for hr-HPV test was 48.3 and PPV was 22.5.  p16/Ki-67 Dual 
immunocytochemistry with more than ten cells cutoff showed significantly improved 
specificity (93.9 vs 70), PPV (82.4 vs 53.1) and decrease in sensitivity (73.7 vs 89.5) and 
NPV (90.2 vs 94.6%) as compare to a threshold of one or more cells. 
 
 
Figure 19: Performance of P16/Ki-67 immunocytochemistry and hr-HPV test in 
detection of ≥ CIN2 lesions in reproductive age group women 
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Images: 
 
Figure 20: Positive control of p16/Ki-67 dual ICC at 40x 
 
Figure 21: Positive control of p16/Ki-67 dual ICC at 200x.  
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Figure 22: Negative control of p16/Ki-67 dual ICC at 200x   
 
 
Figure 23: Negative control of p16/Ki-67 dual ICC at 200x  
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Figure 24: P16/ki67 dual ICC- ASCUS at 200x. 
 
 
Figure 25:  P16/Ki-67 dual immunocytochemistry -LSIL at 200x 
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Figure 27: P16/Ki-67 dual ICC- ASC-H at 200x 
 
Figure 27: P16/Ki-67 dual ICC - HSIL at 200x 
84 
 
 
 
 
DISCUSSION 
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Cervical cancer is still one of the major causes of death worldwide, particularly more 
common in developing countries.  Pap smear is still one the most efficient tests used for 
screening of cervical carcinoma in many countries. The disadvantage of using Pap smear 
is that it has low sensitivity and relatively high specificity.  Since the awareness about 
association between cervical carcinoma and human papilloma virus, high risk HPV DNA 
test was implemented as a potential screening test to improve the sensitivity and to 
identify 13 high risk types of HPV. 
This test had shown good sensitivity when compared to Pap smear screening but it has 
low specificity. Presence of persistent hr- HPV was associated with more risk of 
developing precancerous cervical lesion followed by invasive malignancy due to 
dysregulation of cell cycle by incorporation oncogenic viral proteins into the host 
genome.  
This hr-HPV test identifies all women infected with hr- HPV types, irrespective of the 
nature of infection. Most of the infections which were transient in nature resulted in 
clearance of high risk infection within 1-2 years. However, the triage of minor cervical 
cytology abnormalities is still not clear. If hr-HPV test is positive, then such patients are 
referred for colposcopy guided biopsy to rule out any precancerous or cancerous lesion. 
Since hr-HPV test has low specificity, particularly in the younger age (<30 years), there 
is an increased number of unnecessary referral to colposcopy which is associated with 
more morbidity. This also discourages the women from participating in screening 
programs, due to multiple repeated tests. 
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Thus, it was important to find out a better triaging test for hr-HPV positive women or 
women with minor cytological abnormalities to reduce the number of false positive cases 
and thereby to reduce the number of unwanted colposcopies and biopsies. One of the 
relatively recently introduced triage system for these cases is immunocytochemistry 
p16/Ki-67. p16 is a protein which triggers the cell cycle arrest under normal 
physiological state and Ki-67 indicates proliferating index of a cell. Co-expression of 
both p16 and Ki-67 in a same cell indicates dysregulated cell cycle due to incorporation 
viral oncoprotein into the host genome suggestive of an underlying high-grade lesion. 
Our study is a prospective diagnostic study which evaluated performance of dual stained 
immunomarker p16/ki-67 with HC2 HPV assay in cervical screening for detection of 
high grade cervical intraepithelial lesion in abnormal Pap smears.  This study included 42 
ASC-US, 16 LSIL, 14 ASC-H and 22 HSIL cases of abnormal Pap smears from August 
2016 to March 2017 for analysis. 
The median age was 42.73 years (standard deviation of 11.4 years) for abnormal pap 
smears and was comparable to median age of 41 (Korolczuk et al, 2015).  ASC-US was 
the most common group in the study. Nayar et al in the Bethesda system for reporting 
cervical cytology shown that ASC-US most is the most common abnormal cytology 
group. 
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Performance of p16/Ki-67 and hr-HPV test: 
In our study the performance of dual immunocytochemistry for high grade (≥ CIN2) 
lesion was as follows: sensitivity 96.8%, negative predictive value 97.6%, specificity 
70.2% and positive predictive value of 61.2%. Thus, for detecting high grade lesions (≥ 
CIN2) among all abnormal Pap smears, sensitivity and negative predictive value of dual 
immunocytochemistry was similar to HC2 HPV DNA testing, but with improved 
specificity and positive predictive values.  
These results were comparable to You-Lin Qiao et al study (71). You-Lin Qiao et al in 
2015performed cytology-based screening in total population of1290 women including 
pre -cancerous and cancerous lesions in china. You-Lin Qiao et al highlighted 
performance of p16/Ki-67 dual immunocytochemistry as following; sensitivity was 
90.2% (94.4% hr- HPV test), specificity was 79.5% (76.9% for hr-HPV test), positive 
predictive value was 49.2% (47.1 for hr- HPV test), and negative predictive value was 
97.6% (98.4% for hr- HPV test). You-Lin Qiao et al study highlighted high sensitivity 
and negative predictive value for hr-HPV test as compare to dual immunocytochemistry 
whereas our study showed similar results for sensitivity and negative predictive value for 
both tests (Table:10) The present study showed better specificity and positive predictive 
value for dual immunocytochemistry as compared to hr-HPV test which is similar to 
You-Lin Qiao et al study results. 
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 Our study: 
N=94 
P16/Ki-67 
You-Lin Qiao 
et al, N=1079 
p16/Ki-67 
Our study: 
N=94 
Hr-HPV 
You-Lin Qiao 
et al, N=1079 
Hr-HPV 
 
Sensitivity 
 
 
96.8% 
 
90.9% 
 
96.8% 
 
94.4% 
 
Specificity 
 
 
70.2% 
 
79.5% 
 
55.8% 
 
76.9% 
 
PPV 
 
 
61.2% 
 
49.2% 
 
51.7% 
 
47.1% 
 
NPV 
 
 
97.6% 
 
97.6% 
 
97.6% 
 
98.4% 
 
Table 16: Comparison of performance of p16/Ki-67 vs hr-HPV test in our study 
with other study 
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A few studies have highlighted the difference between the performance of dual 
immunocytochemistry for less than 30 and more than 30 years of age (Table 
11).Bergeron et al showed performance of p16/Ki-67 in LSIL for women < 30 years and 
>30 years as follows: sensitivity(84.6% vs 86.5%), specificity (50%vs56%), PPV 
(23.2vs29.4%) and NPV (94.8 vs 95.1) whereas Peter Ziemke 2017 study results were 
following, sensitivity(81.6 vs 84.6), specificity(61.1 vs 75.7), PPV(42.5 vs 52.8) and 
NPV (90.4 vs 93.8%). Above studies show that performance of p16/Ki-67 for women 
more 30 years was better as compared to women less than 30 years. 
Table:17: p16/Ki-67 immunocytochemistry and age dependency for LSIL cytology 
in different studies 
 
Author  Age  number Sensitivity Specificity PPV NPV 
 
Bergeron, 
2015 
 
 
<30 years 
 
>30 years 
 
172 
 
212 
 
84.6 
 
86.5 
 
50 
 
56 
 
23.2 
 
29.4 
 
94.8 
 
95.1 
 
Peter 
Ziemke, 
2017 
 
<30 years 
 
>30 years 
 
146 
 
185 
 
81.6 
 
84.6 
 
61.1 
 
75.7 
 
42.5 
 
52.8 
 
90.4 
 
93.8 
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Table 18: Comparison of performance of p16/Ki-67(threshold of ≥ 1 cell) vs  
hr-HPV test in less than 30 years and more than 30 years in our study 
 
 
 
 
 
 
 
 
 
 
In our study, performance of dual immunocytochemistry was following between less than 
30 years and more than 30 years:  sensitivity (100 vs 93.5), specificity (36.4 vs 76.5), 
positive predictive value (14.3 vs 70.7), negative predictive value (100 vs 95.1) The 
specificity and positive predictive value were much better for women more than 30 years 
as compared` to less than 30 years.  Bergeron, 2015 and Peter Ziemke, 2017 also arrived 
at similar results, though they had looked only at LSIL. 
 <30 years 
P16/Ki-67 
>30 years 
P16/Ki-67 
<30 years 
 
Hr-HPV test 
 
>30 years 
Hr-HPV test 
 
Sensitivity 
 
100 
 
93.5   
 
100 
 
93.5% 
 
Specificity 
 
36.4 
 
76.5    
 
45.5 
 
56.9 
 
PPV 
 
14.3 
 
70.7  
 
12.1 
 
56.9 
 
NPV 
 
100 
 
95.1  
 
100 
 
93.5 
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Peter Ziemke in 2017, proposed that false positivity in older women is less as compared 
to women less than 30, due to the longer infective period in older women. It could also be 
a good indicator of reparative and productive function of younger women. Peter Ziemke 
further demonstrated in the same study, increased specificity and predictive value when 
cutoff for dual immunocytochemistry positivity was more than 10 cells. Using a score of 
10 P16/Ki-67 marked cells as a positive result instead of 1 led to significantly higher 
specificity (89% vs 70.2%) and positive predictive value (55.7% vs 46.7%) among 
women in LSIL group.  
In our study, including all age groups, when we increased the cut off for positive 
interpretation to 10 cells, there was significantly increase in specificity (90.2 % vs 70.2%) 
and positive predictive value (89.3% vs 61.2%) whereas sensitivity (96.8 vs 78.1) and 
negative predictive value (97.6% vs 89.2%) relatively decreased. 
In women less than 30 years, specificity was 36.4% and positive predictive value was 
14.3% with a threshold of ≥1cell. When we used cutoff of more than 10 cells, the 
specificity (90% vs 36.4%) and positive predictive value (50%vs14.3) increased 
significantly with no significant change in sensitivity and negative predictive value. This 
was due to reduction in the false positivity. Since the number of women <30 years in our 
study was low, statistical significance cannot be demonstrated. However, results show 
that if cut off was increased to more than 10 cells, number of false positive cases were 
reduced, resulting in increased specificity and positive predictive value. 
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In women more than 30 years, there was increase in specificity (96.1 vs 76.5) and 
positive predictive value (92.3 vs 70.7) but decrease in sensitivity (77.4 vs 93.5) and 
negative predictive value (87.5 vs 95.1).   
Thus, increasing the cut off for dual immunocytochemistry, resulted in significantly 
increased specificity and positive predictive value and relative decrease in sensitivity and 
negative predictive value.  These results were similar to that of Peter Ziemke, though he 
has included only the LSIL cases. 
Performance of p16/Ki-67 (threshold of ≥ 1 cell) and hr-HPV among low 
grade cytological abnormalities:  
We further assessed the performance of the dual immunocytochemistry and hr-HPV test 
among LSIL group, which was as follows: sensitivity (100% vs100%), negative 
predictive value (100% vs 100%), specificity (64.3%vs 26%) and positive predictive 
value (28.6% vs 09.09%) for high grade lesion (≥ CIN2).  Hence, sensitivity and negative 
predictive value were similar (100%) for dual immunocytochemistry and hr-HPV test. 
However, dual immunocytochemistry showed better specificity and positive predictive 
value as compared to hr-HPV test.  Our study results were comparable to Bergeron et al 
study results. 
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Table 19: Comparison of performance of p16/Ki-67and hr-HPV test in LSIL 
 
 
 
 Our study 
N=16 
P16/Ki-67 
Bergeron, 2015 
N=384 
P16/Ki-67 
Our study 
Hr-HPV 
Bergeron, 2015 
Hr-HPV 
 
Sensitivity 
 
100% 
 
85.7% 
 
100% 
 
98.4% 
 
 
Specificity 
 
64.3% 
 
78.7% 
 
26% 
 
15.6% 
 
 
PPV 
 
28.6% 
 
16.3% 
 
09.09% 
 
18.6% 
 
 
NPV 
 
100% 
 
99.7% 
 
100% 
 
98% 
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Bergeron et al and a few other studies, also assessed the performance of p16/ki-67 
immunocytochemistry marker in ASC-US   In our study, performance of p16/Ki-67 dual 
immunocytochemistry results among ASCUS group as compared to hr-HPV test was 
follows: sensitivity (100% vs 100%), NPV (100% vs 100%), specificity (82.1% vs 
71.8%) and PPV (30.1% vs 21.4%) for high grade lesions (≥ CIN2). Present study 
showed that sensitivity and NPV were similar (100%) for dual immunocytochemistry and 
hr-HPV. However, dual immunocytochemistry showed better specificity and PPV as 
compare to hr-HPV test.  Our study results were comparable to Bergeron et al study 
results. 
 
Table 20: Comparison of performance of p16/Ki-67and hr-HPV test in ASCUS 
 
Our study 
N=42 
P16/Ki-67 
Bergeron, 2015 
N=427 
P16/Ki-67 
Our study 
N=42 
Hr-HPV 
Bergeron, 2015 
N=427 
Hr-HPV 
 
Sensitivity 
 
100% 
 
94.4% 
 
100% 
 
100% 
 
Specificity 
 
82.1% 
 
78.7% 
 
71.8% 
 
60.4% 
 
PPV 
 
30.1% 
 
16.3% 
 
21.4% 
 
10% 
 
NPV 
 
100% 
 
99.7% 
 
100% 
 
100% 
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In our study one case of ASC-H with negative hr-HPV and dual immunocytochemistry 
had CIN2 on biopsy. In the study by You-Lin Qiao et al, 21 cases of ≥ CIN2 (21/231) 
lesions, were p16/Ki-67 negative. It indicates that not all precancerous lesions progress to 
cervical cancer(71). There was evidence that approximately 40% of undiagnosed CIN-2 
will regress over 2 years. This could possibly explain the negativep16/Ki-67 
immunocytochemistry. This case was also negative for hr-HPV test. Marianne 
Waldstrom et al in 2012 shown that4 cases of CIN2+ (4/133) lesion, were negative for 
both hr-HPV test and p16/Ki-67. (72) 
The kappa agreement for dual stained immunocytochemistry for CIN2+ was higher when 
compared to hr-HPV test (0.559 vs 0.406). When higher threshold of more than 10 cells 
is used the agreement was (0.754 vs 0.559), suggesting thatP16/ki-67 test could be a 
better test as compared to hr-HPV test. 
The present study performed in 94 women with abnormal Pap cytology, showed similar 
sensitivity and negative predictive value but increased specificity and positive predictive 
value for dual immunocytochemistry as compared to hr-HPV test. This data is concordant 
with literature. Since p16/ki-67 has better specificity and positive predictive value than 
hr-HPV test, it can be used as a triage for hr-HPV positive women. The disadvantage is 
that when one cell is used as a cutoff for positive interpretation, the specificity and 
positive predictive value were less. This could be due to increased number of false 
positivity particularly in younger women.  By increasing the cut off to at least 10 positive 
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cells, there was increased specificity and positive predictive value, However, with 
decrease in sensitivity and negative predictive value. 
There are more alternative newer triage tests emerging and under study for hr-HPV 
positive women, to improve the predictive values of high grade lesions. Even though 
most of the other triage methods are not yet approved for screening program, few studies 
such as methylation assay based molecular technique are being extensively studied in the 
recent times. (73) 
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CONCLUSIONS 
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1. ASC-US was the most common intraepithelial lesion in all age groups.  
2. 80% of women were symptomatic and 20% of women were asymptomatic. 
3. Bleeding per vagina was the most common presenting symptom. 
4. Sensitivity (96.8%) and negative predictive value (97.6%) for hr-HPV test and 
p16/Ki-67 dual immunocytochemistry (≥ 1 positive cell) were similar, but the 
latter test showed better specificity (70.2 vs 55.8) and positive predictive value 
(61.2 vs 51.7) for ≥ CIN 2 lesions.  However, this is not statistically significant. 
5. 20% cases showed false positivity for p16/Ki-67 dual immunocytochemistry and 
30% for hr-HPV test. 
6. A higher cut off of at least 10 positive cells gives a clinically and statistically 
higher specificity (CI: 25 to 52) and positive predictive value (CI: 20 to 54), while 
however, slightly decreased sensitivity and negative predictive value. 
7. Since High risk HPV test has high sensitivity and negative predictive value while 
P16/Ki-67 dual immunocytochemistry (≥ 10 positive cells) has high specificity 
and positive predictive value, the latter can be recommended as an ancillary test in 
hr-HPV test positive women, to reduce the number of women going for 
colposcopy and biopsies. 
8. Thus P16/Ki-67 dual immunocytochemistry can be used for risk stratification and 
also for appropriate management in patients with ASCUS and LSIL.  
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LIMITATIONS 
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Due to a delay in acquiring the CINtec plus kit for immunocytochemistry, the 
residual samples and premade smears were kept in the refrigerator for up to 100 
days, which resulted in many paucicellular and inadequate smears, which had to 
be excluded from the study. 
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Appendix: 01 
 
Protocol for thin prep cervical smear: 
 
1. PreservCyt solution is a media used for collection of and preservation of cells and 
DNA of patient samples.   
2. All specimens were subjected to standard methods of cell processing. 
3. All residual samples were placed inside the refrigerator 2-4 degree Celsius. 
4. Thin Prep®) slides prepared on a Thin Prep® 2000 Processor (Hologic™ Inc.) 
according to the manufacturer’s protocol.   
5. The residual sample in the container was placed inside the instrument.   
6. Cell suspension was homogenized and cells were settled on a ﬁlter membrane and 
transferred to a glass slide.  
 
Appendix:02 
 
Protocol for Hr-HPV DNA test: 
1. Label hybridization plate, prepare denaturation reagent. 
2. Pipette denaturation reagent (volume is equivalent to half of the specimen volume) 
into calibrator, quality control and specimen. Check that all tubes show purple 
colour. 
3. Cover rack with film and lid. 
4. Vortex for 10 seconds 
5. Incubate at 65± 2-degree C for 45± 5 minutes. 
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6. Prepare HPV probe mix. 
7. Microplate heater 1 method used for following steps. Mix denatured specimen well 
and pipette 75ul into microplate wells. 
8. Incubate for 10 minutes at 20-25-degree C 
9. Pipette 25ul high risk HPV probe mix into microplate wells. 
10.   Cover microtubes with a plate sealer and shake on rotary shaker 1 at 1100 ±100 
rpm for 3± 2 minutes. Check that all wells show yellow colour. 
11.   Incubate at 65±2-degree C for 60± 5 minutes. Prepare capture microplate. 
12.  Transfer contents from each hybridization plate well to corresponding well in 
capture microtube. 
13.  Shake at 1100±100 rpm at 20-25-degree C for 60± minutes. Prepare wash buffer. 
14.  Decant and blot capture microplate. 
15.  Pipette 75ul detection reagent 1 into each well of capture microplate. Incubate at 
20-25-degree C for 30-45 minutes. 
16.  Manual washing method is used for washing 6 times. 
17.  Blot on lint-free paper towels. 
18.  Pipette 75ul detection reagent 2 into each well of capture microplate. Incubate at 
20-25-degree C for 15-30 minutes. 
19.  Read capture microplate on luminometer. 
20.  Validate assay and interpret specimen results. 
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Appendix: 03 
 
Protocol for manual staining of CINtec dual immunostaining kit: 
Thin Prep slides should be fixed in 100% ethanol for 10 minutes to 1 hour and then air-
dried for 20 minutes.  The kit contains reagent volume which is sufficient to perform 50 
tests. 200 μL per slide is recommended to process Thin Prep® cytological preparations. 
 
I.  Reagent Preparation 
It is recommended to prepare the following reagents, except the Fast-Red working 
solution, before starting with the staining procedure. All reagents should be equilibrated 
to room temperature (20 – 25°C) prior to immunostaining. 
1. Epitope Retrieval Solution 
Prepared by dilution of a quantity of Epitope Retrieval Solution 1:10 using distilled or 
deionized water. 
2. Wash Buffer 
Prepared by diluting of a quantity of the Wash Buffer (10 x) 1:10 using distilled or 
deionized water. 
3. Substrate-Chromogen Solutions (DAB and Fast Red) 
Chromogens and Substrates are equilibrated to room temperature (20 – 25°C).  
A) Preparation of the DAB working solution prior to the staining run 
i) One mL of the DAB Substrate Solution into a clean reaction tube; 
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ii) Add one drop (25 – 30 μL) of the DAB Chromogen and mix gently by inverting the 
tube (do not vortex) 
B) Preparation of the Fast-Red working solution directly before use 
  Fast Red working solution directly before use. Do not vortex 
1. One mL of the Naphthol Phosphate Substrate Solution into a clean reaction tube. 
2. Add one drop (40 – 45 μL) of the Fast-Red Chromogen and mix gently by inverting 
the tube (do not vortex) 
4. Counterstain  
The DAB and Fast Red staining reactions result in water insoluble coloured end product 
(DAB: brown; Fast Red: red). 
Alcohol-free hematoxylin must be used for counterstaining. 
  5 Mounting Medium. 
CINtec® PLUS Mount, an aqueous-based permanent mounting medium, is applied in a 
thin coat and allowed to dry (“liquid cover slipping”). 
 
II. Staining Procedure: 
1. Specimen rehydration 
For all cytological specimens a rehydration step is necessary prior to staining. This step 
should be performed at ambient temperature (20 - 25°C). Slides are kept in distilled or 
deionized water and incubate for 10 (±3) minutes. 
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2.  Epitope Retrieval 
• Fill heat resistant staining jars (plastic) with the diluted Epitope Retrieval Solution. 
• Place staining jars containing Epitope Retrieval Solution in water bath and heat water 
bath and the Epitope Retrieval Solution to 95 – 99°C. 
• When the temperature of 95 – 99°C has been reached immerse the rehydrated 
cytology slides into the preheated Epitope Retrieval Solution in the staining jars. 
• Incubate for 10 (±1) minutes at 95 – 99°C. 
• Remove the entire jar with slides from the water bath. 
• Remove the lid off the staining jars and allow the slides to cool in the Epitope Retrieval 
Solution for 20 (±1) minutes at ambient temperature until it has reached 50°C or below. 
• Transfer the slides into a staining jar filled with Wash Buffer and incubate for 5 (±1) 
minutes prior to staining. 
3. Steps for staining: 
1. Equilibration: Keep the slides with Wash Buffer (2 mL) and incubate for 5 minutes to 
allow the wash. 
2. Apply 200 μL Peroxidase Blocking Reagent. Incubate for 5 minutes. 
3. Keep the slides in wash buffer (2 mL) and incubate for 5 minutes. 
4. Apply 200 μL Primary Antibodies Solution (p16INK4a/Ki-67). Incubate for 
30minutes. 
5. Keep the slides in Wash Buffer (2 mL) and incubate for 5 minutes. 
6. Apply 200 μL Visualization Reagent HRP. Incubate for 15 minutes. 
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7. Keep the slides in Wash Buffer (2 mL) and incubate for 5 minutes. 
8. Apply 200 μL Visualization Reagent AP. Incubate for 15 minutes; 
9. Keep the slides in Wash Buffer (2 mL) and incubate for 5 minutes. 
10. Apply 200μL DAB Substrate-Chromogen Working Solution and incubate for 10 
minutes. 
11. Keep the slides with distilled or deionized water (2 mL) and incubate for 5 minutes. 
12. Put the slides in Wash Buffer (2 mL) and incubate for 5 minutes. 
13. Apply 200 μL Fast Red Substrate-Chromogen Solution and incubate for 15 minutes. 
14. Keep the slides in Wash Buffer (2 mL) and incubate for 5 minutes. 
15. Add 200 μL Alcohol-free hematoxylin must be used for counterstaining for 15 
minutes. 
16. Permanent mounting medium, is applied in a thin coat and allowed to dry. 
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  Department of Gynecological Oncology, Christian Medical College 
                                           Information sheet 
You are requested to participate in a study to see the significance of p16/ki67 
immunocytochemistry in improving the efficiency of the screening system for cervical 
cancer in pap smear. 
What is pap smear and p16/ki67 immunocytochemistry?  
Cervical cancer is a common disease among women in India. Cervical cancer has a high death 
rate.  This cancer is usually screened for by a special test called PAP test. This test uses a spatula 
to obtain samples from the cervix. These samples are processed into smears which are then 
subsequently assessed for the presence of cancer cells and categorized according to the risk for 
cancer as ASCUS/LSIL/ASC-H and HSIL. The categories with the lowest cancer potential 
include ASCUS and LSIL. It has been found that these two categories despite being regarded as 
low risk for cancer, also have 5-30% chance of having an underlying cancer. Currently hr-HPV 
DNA test is used in low grade risk group to identify high grade lesion. If above test is positive 
patient will be directed for colposcopy. This study proposes to employ special cancer markers 
(p16/ki67) to help more accurately identify the presence of cancer cells on Pap smears in the 
lesions. Hence if this study is significant, we can avoid unwanted colposcopy examination and 
can improve the efficiency of cervical cancer screening system.  
What is colposcopy?  This is a standard method of evaluating the cervix or entrance to 
the uterus. It requires standard gynaecological examination using a speculum to see the 
cervix, A good light and magnification system is used to look at the cervix. During 
colposcopy diluent vinegar acetic acid will be applied on the cervix and changes in colour 
noted. If there are abnormal areas, a small biopsy will be taken to confirm cervical pre-
cancer or cancer. Even if colposcopy does not show abnormal areas, a 4-quadrant biopsy 
will still be performed to rule out a precancerous lesion.  
Does colposcopy have any side effects?  As with any gynaecological examination there 
may be discomfort and embarrassment of a speculum examination. 
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If you take part what will you have to do?  Colposcopy will be used to look at the 
cervix. Diluent 3% acetic acid will be applied on the cervix. Abnormal areas may be 
biopsied. You may have to return and obtain the biopsy result if it has been taken. If 
biopsy show any abnormality, you will be treated appropriately. It is always better to treat 
pre- cancer and cancer as early possible.  
Can you withdraw from this study after it starts? Your participation in this study is 
entirely voluntary and you are free to decide to withdraw permission to participate this 
study.  
What will happen if you develop any study related injury? We do not expect any 
injury to happen to you but if you do develop any side effects or problem due to the 
study, these will be treated and no cost to you. We are unable to provide any monetary 
compensation. 
Will you have to pay for the study? Colposcopy will be done without charge. You need 
to pay for biopsy. 
What happens after the study is over ?We will be able to know whether p16/ki67 dual 
immunostaining will be useful in improving the efficiency of the screening system for 
cervical cancer. So that in the future, it will be recommended in abnormal pap test. 
Will your personal details be kept confidential? The results of this study will be 
published in medical journal but you will not be identified by name in any publication or 
presentation of results. However, your medical data noted may be reviewed by people 
associated with the study without your additional permission. 
If you have any further questions, please ask. 
Dr. Vinoth Kumar (9952541163)             E-mail: rogervinoth@gmail.com. 
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Informed Consent Form for Subjects 
Study Title: To assess the significance of p16/ki67 immunocytochemistry in improving 
the efficiency of the screening system for cervical cancer. 
Study Number: ____________     Subject’s Name: ______________ 
Date of Birth / Age: ___________________ 
(i)  I confirm that I have read and understood the information sheet dated 
___________for the above study and have had the opportunity to ask questions. [  
] 
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [  ] 
(iii)  I understand that, the Ethics Committee and the regulatory authorities will not 
need my permission to look at my health records both in respect of the current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the trial. I agree to this access. However, I understand that my 
identity will not be revealed in any information released to third parties or 
published. [  ] 
(iv)  I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). [  ] 
(v)  I agree to take part in the above study. [  ] 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
Date: _____/_____/______ 
Signatory’s Name: _________________________________         Signature:  
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Clinical Research Form 
 
• Title:  To improve the predictive value to identify CIN 2+ lesion in cervical 
pap smears by using novel p16/ki67 immunocytochemistry test. 
 
• SI No:                                                                               Date:  
• Name:  
•  Age: 
• Hospital No:  
• Cytology No:  
• Histopathology- Biopsy No:              
• Indication for cervical screening: Routine cervical screening / Symptomatic                                                                           
• Presenting symptoms: Irregular bleeding per vaginum / Discharge Per vaginum / 
Growth / Ulcer. 
• Duration of illness:  
• Examination findings: 
• Marital status: Married / Unmarried 
• Menstrual status:  
• Menopause – Yes/No 
• If yes, since how many years? 
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Step - 1:  Cervical pap smear screening:  Negative/ reactive change/ ASC-US/ LSIL / 
ASC-H/ HSIL/ AGC/ SCC/ Adenocarcinoma. 
Step-2:  hr-HPV DNA test: Positive / Negative. 
Step-3:  Dual immunostaining p16/ki67: Positive/Negative. 
Step-4:  Colposcpy examination: Satisfactory / Positive / Negative. 
Step-5:  Biopsy in colposcopy positive cases: Negative/ Reactive changes/ CIN1 /CIN11 
/ CIN111 / Invasive malignancy. 
 
 
 
SI.NO hr-HPV p16/ki67 dual 
immunocytochemistry 
Colposcopy Biopsy 
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Data Sheet 
 
 
 
 
 
 
 
 
 
 
slno age cytology biopsyno cervical presentsym durillness marital parity menopause menoyes papsmear dnatest dualimmuno ifposcells cell colposcpy biopcolp
1 60 P16-13089 32402/6 1 1 3 1 7 4 1 1 3 3 2 7
2 61 P16-14508 36058/16 2 5 1 3 1 4 1 2 2 2 2 3
3 30 P16-13495 37017-17 2 2 30 1 3 2 1 2 2 2 2 1
4 47 P16-14523 36042/16 2 1 2 1 3 2 1 2 2 3 5
5 46 P16-15561 38187/16 2 1 18 1 3 2 1 2 2 1 5
6 45 P16-15888 38362/16 2 3 1 2 2 1 1 2 3 3
7 26 P16-15453 39363-16 2 1 1 3 2 4 1 1 2 3 3 3
8 57 P16-15804 39261/61 1 1 2 1 10 3 1 1 2 3 1 5
9 49 P16/15432 39265/16 1 1 3 1 2 1 2 1 2 3 1 3
10 29 P16-14395 39267/16 2 5 1 3 2 1 2 1 2 3 1 3
11 54 P16-16012 38851/16 2 1 12 1 3 2 2 1 1 3 3 2 6
12 60 P16-14713 39427/16 2 5 1 3 1 10 1 2 2 3 1 2
13 34 P16-16003 39774/16 2 1 6 1 3 2 1 2 2 3 3
14 42 P16-16394 39792-16 2 2 24 1 2 2 1 2 2 3 3
15 29 P16/16005 39853/16 2 5 1 1 2 1 2 2 3 3
16 37 P16-16407 39818/16 2 1 48 1 3 2 4 1 1 3 3 2 6
17 36 P16-15729 39970/16 2 1 12 1 3 2 2 1 2 3 1 3
18 35 P16-15899 39986/16 2 1 36 1 2 2 1 2 2 3 3
19 70 P16-16856 40742/16 2 1 1 1 3 1 25 4 1 1 3 3 2 8
20 23 P16-16824 41021/16 2 5 1 3 2 3 1 1 2 3 1 5
21 52 P16-16906 41139/16 2 1 0.12 1 3 1 2 1 2 2 3 1 3
22 45 P16-17402 42082/16 2 1 60 1 3 2 4 1 1 3 3 2 7
23 51 P16-16544 41700/16 2 5 24 1 3 1 1 3 1 1 3 3 1 6
24 33 P16-17603 42593/16 2 5 36 1 3 2 1 2 2 3 1 3
25 27 P16-17522 42730/16 2 1 2 2 2 1 1 2 3 3 3
26 40 P16-15496 15496/16 2 1 1 3 2 1 1 1 3 3 6
27 26 P16-17882 4448/16 1 1 3 2 1 2 2 3 1 3
28 61 P16-18306 44436/16 1 1 3 1 6 1 1 2 3 1 3
29 45 P16-18773 44855/16 2 5 3 1 3 2 3 2 2 3 1 4
30 42 P16-18133 48864/16 2 6 6 1 3 2 1 2 2 3 1 3
31 33 P16-18388 4956/17 2 1 12 1 3 2 4 1 1 3 3 2 7
32 42 P16-19095 45073/16 2 1 60 1 3 2 1 2 2 3 2 2
33 41 P16-19453 46380/16 2 1 4 1 3 2 1 2 2 3 3 2
34 45 P16-20443 39/17 2 1 4 1 3 2 4 1 1 2 3 8
35 36 P16-20285 639/17 2 1 1 1 2 2 1 2 2 3 1 3
36 47 P17/2067 1061/17 2 1 72 1 3 2 4 1 1 3 3 3 6
37 31 P17-152 1605/17 1 2 2 1 2 3 4
38 40 P17-643 2870/17 2 1 1 2 2 4 1 1 3 3 2 6
39 63 P17-1280 2481/17 2 1 1 3 1 7 4 1 1 3 3 8
40 72 P17-1743 5226/17 2 1 0.15 1 3 1 15 1 2 2 3 3 3
41 26 P16-7882 44448/16 1 1 3 2 1 2 2 3 1 3
42 47 P16-19680 46998/16 2 2 2 1 3 1 3 4 1 1 3 3 2 8
43 36 P16-19398 46992/16 2 2 0.4 1 3 2 4 1 1 3 3 2 7
44 70 P16-19526 47000/16 1 1 3 1 26 1 1 1 2 3 2 6
45 43 P16-19620 47371/16 2 1 1 1 3 2 1 1 1 3 3 2 3
46 43 P16-14512 35464/16 2 1 1 3 2 1 2 2 2 3
47 40 P16/18039 47388/16 2 1 2 1 3 2 2 1 1 2 3 1 5
48 28 P16-20088 47946/16 2 2 1 3 2 3 1 1 3 3 2 6
49 36 P17-1026 207/17 2 1 1 3 2 2 1 2 3 2 4
50 62 P16-20431 203/17 2 7 1 3 1 12 1 2 2 3 2 5
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51 35 P16-20285 639/17 2 5 1 3 2 1 2 2 3 3 3
52 32 P17-337 17-337 1 1 2 1 1 2 3 2 3
53 47 P16-20671 1060/17 2 1 72 1 3 2 4 1 1 3 3 6
54 21 P17-544 41/17 1 1 3 2 3 1 1 2 3 2 4
55 58 P16-20493 7339/17 1 1 3 1 10 1 1 1 3 3 2 6
56 49 P17-1219 4260/17 2 5 1 3 1 4 3 1 1 2 3 2 5
57 46 P17-1519 4547/17 1 1 2 1 1 1 2 2 2 2 3
58 41 P16-19012 4292/16 2 5 1 1 2 2 1 1 2 3 2 3
59 39 P16-15851 38514/16 1 1 2 2 3 2 2 3 2 3
60 36 P17-2431 5662/17 2 1 0.5 1 3 2 2 1 2 3 1 3
61 36 P17-2249 7631/17 2 1 1 1 2 2 1 1 2 3 2 4
62 46 P17-2725 7579/17 2 1 4 1 3 2 4 1 1 2 3 3 7
63 27 P17-3417 8359/17 2 1 1 2 2 2 1 1 3 2 5
64 39 P17-3019 7628/17 1 1 3 2 3 1 1 3 2 2 2
65 48 P17-1774 4700/17 1 1 2 1 3 2 2 2 2 3 2 5
66 52 P17-585 4694/17 5 1 3 2 3 1 1 3 3 7
67 40 P17-1772 4704/17 2 2 2 1 1 2 1 1 2 3 1 5
68 45 P17-3840 12058/17 2 1 3 2 2 1 1 2 3 1 3
69 40 P17-3962 9482/17 2 1 12 1 2 2 3 2 1 2 3 2 3
70 44 P16-20527 6212/17 2 2 12 1 3 2 1 1 1 2 3 1 5
71 37 P16-16609 41016/16 1 1 2 2 2 1 1 2 3 1 4
72 24 P16-19438 5231/17 2 1 3 1 3 2 1 1 1 3 3 1 3
73 39 P16-19524 4549/17 2 1 3 1 3 2 2 2 2 3 2 3
74 53 P17-5465 13052/17 2 1 3 1 4 4 1 1 3 3 2 7
75 36 917-970 13060/17 2 6 1 3 1 15 1 1 1 2 3 3
76 47 P17-3699 12113/17 2 2 6 1 3 2 4 1 1 3 3 1 8
77 45 P17-3028 6612/17 2 1 2 1 3 2 3 1 1 2 3 2 6
78 43 P17/1042 4698/17 2 2 6 1 3 2 1 2 2 3 2 4
79 40 P17/6610 14850/17 2 1 7 1 3 2 4 1 1 3 3 8
80 44 P16-20620 47212/16 2 1 2 1 3 2 1 2 1 2 3 2
81 34 P16-21993 28819/16 2 2 1 3 2 2 1 2 3 2 3
82 53 P16/2024 2774/16 1 1 4 1 1 3 3 7
83 43 P16-19452 44387/16 2 1 4 1 3 2 4 1 1 3 3 7
84 42 P16-2410 11596/16 2 1 24 1 3 2 1 2 2 3 3
85 60 P16-126 280/16 2 1 12 1 3 1 8 4 1 1 3 3 2 7
86 64 P16-19132 2391/16 2 1 3 1 15 2 1 1 3 3 2 6
87 41 P16-501 2147/16 2 2 60 1 3 2 3 2 2 3 6
88 41 P16-16612 40247/16 2 1 2 1 3 2 1 2 2 2 2
89 65 P16-15933 40596/16 2 5 3 1 3 1 20 4 1 1 3 2 8
90 34 P17-2216 5478/17 2 6 1 2 2 2 2 2 2 3
91 63 P16-19392 46382/16 1 1 3 1 10 1 1 2 2 3
92 59 P17-657 2009/17 2 5 1 3 4 1 1 2 2 7
93 31 P16-18815 46155/16 2 1 5 1 3 2 2 1 2 3 3
94 31 P17-445 13560/17 2 1 5 1 3 2 3 1 2 2 3
